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SUMMARY 
 
 c-Myc, a transcription factor that affects a large number of target genes, is one of 
the most frequently deregulated oncoproteins in human cancer. The wide-ranging 
biological functions of c-Myc include regulation of the cell cycle, differentiation, 
metabolism and growth, protein synthesis and chromatin modifications. For more 
than 25 years, many labs have focused their research on the mechanisms and 
pathways that are affected by c-Myc in normal development and in cancer, including 
breast cancer. However, relatively little was known about the normal physiological 
impact of c-Myc on the mammary gland before this study.  
 To address this open question and uncover the roles of c-Myc during mouse 
mammary gland development, we used a mammary gland specific conditional 
knockout approach, as the full body knockout of c-Myc is embryonic lethal. For this, 
we crossed c-mycfl/fl mice to mice heterozygous for the WAPiCre transgene (Cre 
recombinase under the control of the Whey acidic protein promoter). This resulted in 
c-Myc loss exclusively in the milk-producing, luminal alveolar epithelial cells 
starting in mid-pregnancy. Three major phenotypes were identified in the glands of 
mutant mice. First, we observed that pups nursed by c-Myc mutant mothers grew 
slower compared to pups nursed by wild type mothers. While milk composition was 
comparable between wild type and mutant animals, we found that milk production 
was reduced in c-Myc mutant glands. Electron microscopy revealed that there were 
less secretory vesicles budding from the endoplasmic reticulum in lactating mutant 
cells, suggesting a decreased protein synthesis. By performing polysome 
fractionation experiments we showed that translational efficiency was generally 
decreased in mutant glands. In addition, we found that levels of ribosomal proteins 
and rRNA were lower in mutant glands. Interestingly, analyzing mRNA distribution 
along the polysome gradient demonstrated that mRNAs whose protein products are 
involved in milk synthesis were specifically affected while mRNAs of house keeping 
genes were generally unchanged. Our second major finding was that in a second 
round of pregnancy, c-Myc-deficient cells displayed a slower proliferation early 
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during pregnancy. The delayed proliferative response led to delayed but not blocked 
alveologenesis. Finally, the third major observation in c-Myc-deficient glands is 
related to progenitor cells. In mammary transplantation assays, epithelium from 
mutant glands showed a reduced ability to repopulate the glands of female recipients 
compared to epithelium from wild type glands, suggesting a role for c-Myc during 
this process. 
 To summarize, we show here for the first time that c-Myc plays multiple roles in 
the mouse mammary gland. Conditional loss of c-Myc caused delayed proliferation 
and differentiation during pregnancy. During lactation, milk production and 
translation were decreased in mutant glands. Finally, results from transplantation 
studies suggest a role for c-Myc in progenitor cell proliferation and/or survival. 
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INTRODUCTION 
 
I.  Mammary gland development and breast cancer 
 
 The mammary gland is a unique organ of female mammals, which enables them 
to supply their offspring with all essential nutrients via the milk produced in the 
gland. Two features have made the mouse mammary gland a very attractive model 
organ for biological research: first, most of its development occurs after birth and 
second, with every round of pregnancy the organ goes through repeated cycles of 
proliferation, differentiation and apoptosis. The tremendous changes and 
differentiation that convert the organ into a milk synthesizing machine have been 
subject to intense investigation for many years. By deciphering the tightly regulated 
hormone signaling networks, researchers wish to gain insights especially into breast 
cancer susceptibility, development and metastasis. Breast cancer is the second cancer 
worldwide in term of incidence, with 1.29 million out of 12.4 million new cancer 
cases reported in 2008 (World Cancer Report 2008). While large effort has been 
made in the twentieth century and multiple treatments are available, there is, 
depending on the type of breast cancer, much room for improvement. For better 
understanding of the disease, it is indispensable to know the mechanisms in normal 
breast development, starting from the model organism mouse and finding the 
parallels in human breast.      
 
  1.1 development: brief overview 
 The mammary gland consists of two main compartments: the epithelium, forming 
a bi-layered ductal network of luminal and basal cells, and this is embedded in the 
stroma or fat pad, which consists mostly of adipocytes and stromal cells, and also 
contains blood vessels and cells of the immune system. In addition, each fat pad is 
connected to the outside via the nipple, and harbors (at least) one major lymphnode 
(Fig. 1). Development of the gland starts in the embryo as an appendix of the ventral 
skin around embryonic day 10, where the milk line defines the position of the later 
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glands. Various well known signaling molecules regulate the developmental stages 
until birth, at which the gland already consists of a rudimentary ductal tree within a 
stromal fat pad (for detailed review of signaling in embryonic development see 
Robinson, 2007; Watson and Khaled, 2008). At the start of puberty, at around 3 
weeks of age, hormones secreted by the ovaries induce the appearance of highly 
proliferative structures at the tips of the ducts, called terminal end buds (TEB), which 
start to invade the fat pad (Richert et al., 2000). Ductal elongation continues until 
approximately 10-12 weeks of age, when TEBs disappear but secondary and tertiary 
side branches still continue to form in the mature gland during estrus cycles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 When pregnancy occurs, a tremendous proliferation and differentiation cascade is 
initiated, driven by various hormones. After 19-21 days of pregnancy, secretory 
activation occurs at parturition and copious amounts of milk are produced in the 
secretory units, the alveoli. Lactation continues for approximately 3 weeks, when 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
adapted from Hennighausen and Robinson, 2005 
 
Figure 1: Mammary gland development after birth. Pubertal development and 
pregnancy cycle. Age or duration of stage are indicated. TEB: terminal end bud, LN: 
lymphnode.   
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adapted from Sternlicht, 2006 
 
Figure 2: Schematic diagram of a TEB. The characteristic features of the TEB and the 
subtending duct within the stromal surrounding.  
 
pups are weaned and milk stasis induces the complex apoptosis and remodeling 
phase called involution. The fully involuted (after 21 days) gland morphologically 
resembles a virgin-like stage, ready for a next round of pregnancy. The important 
steps during this development are discussed in the following sections in more detail.  
 
 1.2 puberty and estrus cycle 
 After birth, the rudimentary mammary gland grows in parallel to over-all body 
growth (allometric growth) for the first weeks, until levels of the steroid hormones 
estrogen and progesterone rise in puberty and TEBs are formed. The TEBs are highly 
proliferative and migratory structures, which penetrate the fat pad during ductal 
elongation (Ball, 1998). The TEBs consist of two major cell types (Fig. 2): one single 
layer of cap cells, that differentiate into myoepithelial cells in the subtending duct, 
and multiple layers of body cells, which are highly proliferative at the tip of the TEB 
but apoptotic in the inside, thus forming a lumen (Howlin et al., 2006). 
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 Primary ducts are generated by bifurcation of TEBs and, together with the lateral-
sprouting secondary side-branches, they fill the entire fat pad with a ductal network 
(Sternlicht, 2006). The number and size of lateral buds increase with every estrus 
cycle. In mature virgins, during the 4 day estrus cycle, repeated phases of 
proliferation, mild differentiation and apoptosis take place (Andres and Strange, 
1999; Richert et al., 2000). Proliferation is high in late proestrus and estrus, and 
lateral buds develop into tertiary branches or alveolar buds. During estrus, transient 
expression of differentiation markers (i.e. milk proteins) can be detected (Robinson et 
al., 1995). In contrast, regionally restricted apoptosis is prominent during diestrus, 
where whole alveolar structures disappear.  
 Various genetic mouse models have identified hormones, growth factors (GFs), 
transcription factors (TFs) etc. involved in pubertal mammary gland development 
(reviewed in Howlin et al., 2006), of which the 3 main hormones are discussed 
below. The two ovarian hormones, estrogen (E) and progesterone (P), were shown to 
be mostly responsible for ductal elongation and tertiary side branching/alveolar 
expansion, respectively (Hennighausen and Robinson, 2005). Of the two estrogen 
receptor (ER) isoforms, ERα and ERβ, epithelial ERα was shown to be required for 
ductal outgrowth, whereas stromal ERα was not required for wild type (WT) 
epithelium to develop normally (Mallepell et al., 2006). Epithelial ERα acts in a 
paracrine fashion and by inducing expression of amphiregulin, the major pubertal 
EGFR ligand, neighboring cells are stimulated to proliferate (Ciarloni et al., 2007). 
Progesterone receptor (PR) also exists in two isoforms, PR-A and PR-B, of which 
PR-B is reported to be required for normal side-branching while PR-A seems to be 
dispensable (Conneely et al., 2001). Similarly as ER, PR signaling is also thought to 
be paracrine, and Wnt4 was found to be a potential PR target that induces branching 
morphogenesis in vivo (Brisken et al., 2000). The third major influence in the 
pubertal mammary gland is the pituitary growth hormone (GH) and its receptor 
(GHR). Knockout (KO) studies have shown that unlike ER and PR, GHR is required 
in the mammary stroma for successful ductal outgrowth and side-branching (Gallego 
et al., 2001). GHR also functions in a paracrine way, by increasing local IGF-1 
(insulin-like growth factor 1) expression in the mammary gland which, in synergy 
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with estrogen, induces proliferation in neighboring epithelial cells (Kleinberg, 1997; 
for recent review of paracrine factors in the mammary gland see Rosen, 2009). Also 
prolactin (Prl) and its receptor (PrlR) were suggested to play a role during puberty, as 
both Prl-/- and PrlR-/- mice showed severe defects in ductal side branching and TEB 
morphogenesis while prepubertal growth was unaffected (Horseman et al., 1997; 
Ormandy et al., 1997). Transplantation experiments with PrlR-/- tissue into WT hosts 
demonstrated that PrlR-/- epithelium is able to develop normally until pregnancy, 
showing that the effect observed in a full body KO for PrlR is more likely due to 
requirement of endocrine Prl signaling (Brisken et al., 1999).  
 
 1.3 pregnancy and lactation  
 During approx. 19 days of pregnancy, various stimuli induce the massive changes 
that convert the mammary gland into a ‘milk factory’. The development of functional 
alvoeli, alveolar morphogenesis, is a combined process of proliferation and 
differentiation. Ductal proliferation peaks around day 3 of pregnancy and is low 
afterwards. Alveolar proliferation begins to increase around day 5 of pregnancy and 
peaks around day 7 and day 12 (Borst and Mahoney, 1982). Differentiation, also 
called lactogenesis, starts around mid-pregnancy and can be divided into lactogenesis 
I (secretory initiation) and lactogenesis II (secretory activation shortly before 
parturition) (Neville et al., 2002). The involvement of multiple hormonal and GF 
inputs as well as the tremendous changes in gene expression, signaling and 
metabolism are the subject in the following sections.  
  
  1.3.1 start of pregnancy: role of prolactin signaling 
 At the very beginning of pregnancy, initiated by mating activity, Prl is secreted 
from the pituitary, which is the key player in alveolar morphogenesis, together with P 
(Neville et al., 2002). The synergistic action of the two hormones is supported by a 
feedback loop, as Prl stimulates sustained secretion of ovarian P (and also E) and P in 
turn induces expression of PrlR (Oakes et al., 2006). The importance of Prl signaling 
during early pregnancy was demonstrated in heterozygous PrlR+/- mice where 
epithelial cell proliferation was severely impaired leading to lactation failure. 
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adapted from Oakes et al.,  2006; Oakes et al.,  2008 
 
Figure 3: Prolactin signaling during pregnancy. Grey circles indicate receptor specific 
ligands, i.e. P for PR, Prl for PrlR, RankL for Rank, e.g. heregulin for ErbB4 and e.g. 
laminin for β1-integrin. Abbreviations and explanations are given in the text. 
Interestingly, this haploinsufficiency could be partially overcome in subsequent 
pregnancies, which was explained by a requirement for certain levels of PrlR that 
could only be acquired in a second pregnancy (Ormandy et al., 1997). 
Transplantation experiments of PrlR-/- cells into WT hosts revealed that the 
pregnancy related function of Prl signaling was autonomous to the epithelial 
compartment (Brisken et al., 1999).  
 Signaling via Prl and PrlR is mainly mediated via the Jak2-Stat5 pathway (Fig. 3, 
for detailed reviews see Oakes et al., 2006; Oakes et al., 2008). Stat5, originally 
called mammary gland factor, activates transcription of multiple targets involved in 
alveolar morphogenesis, including proliferation, polarity, cell-cell and cell-stroma 
interaction and finally milk protein expression in lactation (Wakao et al., 1995).  
 
  
 
  
 
  
 Signaling via Stat5 is regulated by various positive and negative inputs. Deletion 
of either β1-integrin or ErbB4 resulted in defective alveolar development and Stat5 
phosphorylation (Li et al., 2003; Long et al., 2003; Naylor et al., 2005), showing that 
they are enhancers of the pathway. Negative feedback regulation is provided by 
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members of the Socs family of proteins, which are induced by Prl signaling and 
negatively impact on Stat activation via different mechanisms (Oakes et al., 2008). 
Also caveolin 1 (Cav1), a structural component of caveolae, negatively regulates the 
Prl-Jak2-Stat5 axis (Park et al., 2002). One important downstream target of Prl (and 
P) signaling is RankL, which is a possible paracrine factor mediating proliferation in 
neighboring cells via induction of Cyclin D1. KO studies have shown that Cyclin D1 
is indispensable for the massive proliferation during pregnancy (Sicinski et al., 1995). 
Another potential target of both Prl and P signaling is Wnt4, stimulating a variety of 
possible pathways and targets via β-catenin/TCF signaling. Recently, the Elf5 TF 
was identified as a target of Prl signaling and appears to play a major role in 
mediating alveolar morphogenesis, as expression of Elf5 can largely compensate for 
PrlR loss (Harris et al., 2006; Oakes et al., 2008). Finally, the gap junctions 
component connexin-26 is a direct target of Stat5 and necessary for junctional 
integrity of the forming alveoli (Ormandy et al., 2003). 
 Starting at mid-pregnancy differentiation of alveoli begins, which is also called 
secretory initiation or lactogenesis I. Morphologically, round and hollow alveoli 
form, consisting of a single epithelial layer surrounded by a discontinuous 
myoepithelial layer, thus ensuring direct contact to the basement membrane (Brisken 
and Rajaram, 2006; Richert et al., 2000). Intracellular lipid droplets are characteristic 
for this phase, as expression of milk proteins and lipids increases from then until 
parturition, while active secretion is inhibited by P. At this time, Prl functions are 
mainly taken over by placental lactogen, which was reported to bind to PrlR and 
GHR (Neville et al., 2002).  
  
  1.3.2   secretory activation and lactation 
 Lactogenesis II is induced around parturition by P withdrawal in the presence of 
high Prl levels, thus removing the inhibitory factor. In this phase tight junctions close 
completely to create the alveolar lumen, milk production is further increased, and 
milk components secreted into the lumen (Neville et al., 2002). Figure 4 shows a 
secreting alveolus with zoom on the milk production and secretion pathways within a 
luminal alveolar cell, processes that will be discussed below. Once the pups are born, 
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adapted from Shennan and Peaker, 2000 
 
Figure 4: Alveolus in lactation, zoom on a secreting luminal epithelial cell. 
suckling stimulus and milk removal maintain lactation, with two hormones being 
involved: Prl acting on the luminal epithelial cells to maintain milk production and 
possibly acting as survival signal, and oxytocin, acting on the myoepithelial cells to 
induce contraction and milk ejection (Neville et al., 2002). Oxytocin is released upon 
a suckling stimulus and was shown to be absolutely required for milk release, as 
oxytocin-deficient mice fail to nurse their pups while milk is successfully produced 
in the alveoli. Importantly, injection of oxytocin restores successful release of milk, 
which can be used for experimental milk withdrawal (Young et al., 1996). It was 
further shown that oxytocin and milk removal are an indispensable stimulus for the 
proliferative burst that normally occurs early after parturition (Wagner et al., 1997). 
 
   
 
  
  
  1.3.3   milk: composition, production and secretion 
 Mouse milk is a very rich substance which consists of ~12% protein, 30% lipid 
and 5% lactose (Rudolph et al., 2007). This section will discuss how these 
components are efficiently and coordinately produced in the luminal alveolar cells 
and secreted into the lumen. Recent studies using microarray profiling revealed a 
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large number of genes regulated from pregnancy to lactation, involved in milk 
production and secretion (Rudolph et al., 2003; Rudolph et al., 2007).  
 Lactose is a disaccharide that is unique to milk and functions as the major osmole. 
It is composed of glucose and galactose and synthesized within the Golgi by lactose 
synthase (McManaman and Neville, 2003). The rate-limiting cofactor for this 
enzyme is α-lactalbumin (Soulier et al., 1997), a milk protein, which is one of the 
highly upregulated genes in lactation (Fig. 5). The increased demands of glucose can 
be met by upregulation of the glucose transporter GLUT-1 and downregulation of 
glycolysis enzymes, thus shuttling it towards lactose synthesis (and lipid synthesis, 
see below) (Anderson et al., 2007). Together with other soluble factors, like proteins, 
calcium, ions and water, lactose is secreted in Golgi vesicles via exocytosis into the 
lumen (Fig. 4).  
 Milk proteins are highly upregulated, starting already during pregnancy and 
increasing further after parturition, with the biggest changes in α-lactalbumin and δ-
casein (Rudolph et al., 2003). TFs that regulate the expression of milk proteins also 
increase during pregnancy, such as C/EBPβ for β-casein and Ets for WAP (McKnight 
et al., 1995; Wyszomierski and Rosen, 2001). The caseins, together in a complex with 
calcium and phosphate, form micelles that are visible in electron microscopy (see Fig. 
4; McManaman and Neville, 2003). Numerous studies have been performed, mostly 
using β-casein, to investigate mechanisms of milk protein regulation (reviewed in 
Rhoads and Grudzien-Nogalska, 2007). It is well established now that the increase in 
mRNA is due to increased transcription in combination with an increase in the 
stability of the mRNA. Furthermore, the strong increase in protein synthesis at 
lactation is not paralleled by increased mRNA levels, suggesting a translational 
control. Much evidence suggests that polyadenylation is an important mechanism in 
stabilizing mRNA and enhancing its translation (Rhoads and Grudzien-Nogalska, 
2007).  
 Synthesis of milk lipids is probably the most remarkable task of the mouse 
mammary gland, as the mouse produces its whole body weight in fat during a full 
lactation (Rudolph et al., 2007). De novo triacylglycerol (TAG) synthesis takes place 
in the smooth endoplasmic reticulum (ERet) from fatty acids and a glycerol-
Introduction: Mammary gland 
 
 - 14 - 
     
 
 
adapted from Rudolph et al., 2003; Anderson et al., 2007 
 
Figure 5: Expression changes in the mammary gland during pregnancy and 
lactation, found by microarray or qPCR. Left panel: Milk proteins casein (Csn) α, β, γ, 
κ, milk fat globule-EGF-factor 8, whey acidic protein. Casein δ and α-lactalbumin on right 
axis. Right panel (normalized to P17): Regulatory factors SREBP-1 and Akt1, and glucose 
transporter Glut1. Average profile (dotted line, no scale) of 23 genes involved in fatty acid, 
TAG and cholesterol synthesis. 
phosphate backbone (McManaman and Neville, 2003). Multiple enzymes are 
involved in this multistep process, many of which are highly upregulated during 
lactation (for metabolic map see Rudolph et al., 2007). Glucose again plays a 
prominent role and is processed by different pathways: first, it provides the TAG-
backbone in a reaction involving Aldolase C; second, it generates energy (NADPH) 
via the pentose phosphate shunt and citric acid cycle; and third, it serves as a 
component in generation of fatty acid precursors (Rudolph et al., 2007). Once 
produced, the lipids bud from the smooth ERet, surrounded by one phospholipid 
layer of the ERet, and form cytoplasmic lipid droplets. Those can fuse while being 
transported through the cytoplasm, and finally get secreted in a unique budding 
process through the apical membrane, generating milk fat globules which are coated 
by an additional layer of plasma membrane and sometimes contain parts of the 
cytoplasm (see Fig. 4, left upper corner) (McManaman et al., 2006). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 In the regulation of lipid synthesis, Akt1 (Fig. 5) is discussed to play a major role, 
as constitutive activation of Akt1 leads to excessive lipid synthesis (Schwertfeger et 
al., 2003), while in Akt1-/- mice the glucose transport and transcriptional regulation of 
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enzymes involved in lipid synthesis was impaired (Boxer et al., 2006). One major TF 
in milk lipid synthesis is SREBP-1c which regulates expression of various fatty acid 
biosynthetic enzymes (Goldstein et al., 2006). SREBP-1c is also highly upregulated 
during the transition to lactation and interestingly its active fragment is a member of 
the basic helix-loop-helix TF family, showing that many of the genes involved in 
lipid synthesis are regulated via sterol response elements as well as other TFs 
(Rudolph et al., 2007).  
 
  1.4 involution 
 Involution is the remodeling process following lactation that converts the gland 
back into a pre-pregnancy-like state. In experimental studies, synchronous involution 
can be induced by forced weaning, i.e. removal of the pups after about 10 days of 
lactation, which has been used to reveal many of the mechanisms and regulations 
during this phase (for detailed reviews see Green and Streuli, 2004; Watson, 2006).  
Forced involution can be separated in two distinct phases (Lund et al., 1996): the 
initial phase which is still reversible if pups are returned within 48 hours, and the 
second, irreversible phase that involves intensive tissue remodeling. Full regression 
and reorganization occurs after 21 days.  
 The first phase is characterized by accumulation of shed, caspase-3 positive cells 
in the lumen of the alveoli, which is obvious already after 12 hours (Watson, 2006). 
In experiments where a single teat was sealed it was found that mammary-intrinsic 
signals initiate involution, as only the sealed gland started to involute, and a major 
role seems to be accumulation of milk (Marti et al., 1997). This leads on one hand to 
accumulation of high concentrations of pro-apoptotic factors that normally get 
removed by nursing, and on the other hand to extensive stretching of the alveoli, 
which can possibly activate stretch receptors and disrupt cell-cell adhesions (Green 
and Streuli, 2004). Of the numerous signaling cascades involved in involution (gene 
expression analysis in Stein et al., 2007), a primary role was revealed for the LIF-
Stat3 axis. Deletion of LIF, that is normally 30-fold induced within 12 hours of 
involution, leads to strongly delayed involution (Kritikou et al., 2003), similar to 
what occurs upon deletion of Stat3 (Chapman et al., 1999). Two important target 
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genes of Stat3 in the mammary gland are C/EBPδ and IGFBP-5, the latter inhibiting 
the IGF-1 mediated survival signaling (Green and Streuli, 2004). Interestingly, also 
c-Myc acts downstream of Stat3, and possibly mediates the apoptotic signaling 
(discussed in 3.1.2; Sutherland et al., 2006). 
 In the second and irreversible phase of involution the gland gets completely 
reorganized. The epithelial structures collapse, apoptotic cells get removed by 
phagocytosis (Monks et al., 2005) and stroma and adipocytes are regenerated. 
Important regulators during this phase are serine proteases and matrix 
metalloproteases (MMPs, for detailed review see Green and Lund, 2005). The 
MMPs, whose activity had been inhibited during the first phase by TIMPs, now 
remodel the ECM, thus leading to a second wave of apoptosis due to cell detachment 
and final collapse of the alveoli (Watson, 2006). One open question is how the post-
lactational ductal structures are obtained, if ductal cells are refractory to apoptosis or 
if stem cells regenerate the ducts during involution (Green and Streuli, 2004).   
 
  1.5 stem cells  
 The presence of stem cells in the mammary gland was demonstrated around 50 
years ago, in groundbreaking experiments by DeOme and colleagues (Deome et al., 
1959). They developed an easy and elegant technique, which is still widely used 
today to test tissue for stem cell activity: the cleared fat pad transplantation (Fig. 6). 
In this technique, the gland of a 3 week old recipient mouse (immunocomprimised or 
not) is ‘cleared’ by cutting out the endogenous epithelium, which at that point has not 
yet reached behind the lymph node. The remaining, epithelium-free fat pad serves as 
an environment for pieces of donor tissue. If the piece contained stem cells they will 
be able to repopulate the gland, forming a ductal tree, end buds and even alveoli if 
the recipient is mated. 
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adapted from DeOme et al., 1959 
 
Figure 6: The ‘Cleared Fat Pad’ Transplantation Technique. Transplantation of donor 
epithelium into ‘cleared’ recipient fat pads is a widely used stem cell assay to test in vivo 
outgrowth ability. 
 
   
 
 
  
 
 Using the transplantation technique, numerous results pointed to the existence of 
mammary gland stem cells (reviewed in Smith and Medina, 2008): parts of the 
mammary gland were able to repopulate the fat pad with a normal tree, and 
differentiate under hormonal stimuli. This worked for several series of 
transplantations, although the cells showed signs of senescence after 5 to 8 rounds of 
transplantations. Furthermore, it was shown that every part of the mammary gland 
contained stem cell activity, independently from which stage of development (from 
virgin to lactating or involuted donor). By performing limiting dilution series and 
retrovirally marking of mammary epithelial cells it was found that at least two 
progenitors exist, generating either lobule-limited or duct-limited outgrowths, and 
that they derive from a single pluripotent precursor (Kordon and Smith, 1998; Smith, 
1996). The current hypothesis from transplantation assays suggests that both the 
lobule- and duct-limited progenitors can give rise to luminal epithelial and 
myoepithelial cells, but the lobule progenitor cannot produce cap cells of TEBs while 
the duct progenitor cannot form cells contributing to alveolar development. 
Complementing this model are results from electron microscopy studies, that 
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identified morphologically distinct cells in the mammary gland (Chepko and Smith, 
1997; Smith and Medina, 1988), with the ‘small light cell’ proposed to be a primary 
progenitor cell.  
 In the year 2006, two landmark studies changed the stem cell view and opened 
revolutionary new possibilities: the groups of Connie Eaves (Stingl et al., 2006) and 
Jane Visvader (Shackleton et al., 2006) identified new markers that can be used in 
FACS sorting to isolate potential mammary stem cells. Before that, FACS sorting 
was used to separate cells according to markers known from HSCs, like Sca-1 or 
their ability to efflux Hoechst dye (the so called side population, reviewed in Smalley 
and Clarke, 2005). By using CD24 (heat stable antigen) in combination with either 
CD29 (β1-integrin; Shackleton et al., 2006) or CD49f (α6-integrin; Stingl et al., 
2006) populations highly enriched for mammary stem cell activity were isolated and 
analyzed in in vitro colony forming assays and in vivo transplantation assays. In both 
studies, very few numbers of those cells (down to one single cell with CD24+CD29hi 
or CD24medCD49fhi) were able to reconstitute fully developed outgrowths in serial 
transplants, thus fulfilling the ‘stem cell criteria’ of lineage differentiation and self-
renewal. By further dissecting the CD24 expression levels and ER status in FACS 
sorted populations, the lab of Matt Smalley complemented the results of the other 
groups (Sleeman et al., 2006; Sleeman et al., 2007). Together they generated the 
current view of the mammary stem cell, which is thought to belong to the basal 
compartment (showing low expression of CD24), being negative for ER and high in 
expression of adhesion molecules CD29 and CD49f. The transplantation studies, 
FACS sorting, and use of transgenic mouse models finally led to different hypothesis 
of how the hierarchy of stem cells might look like in the mouse mammary gland, 
with one possible model shown in Figure 7. 
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adapted from LaMarca and Rosen, 2008 
 
Figure 7: Stem cell hierarchy in the mouse mammary gland. One possible model 
based on numerous experimental findings.  
 
  
 
 
 
  
 Note that various different models exist for the stem cell hierarchy, and it has yet 
to be determined which one comes closest to the situation in the mouse. Another 
model suggests the existence of a common ‘luminal progenitor’ that gives rise to both 
ductal and alveolar cells (Visvader and Lindeman, 2006). It is also not yet fully 
understood how to combine these models with the experimental findings discussed 
above, that suggested the existence of a duct-limited progenitor and a lobule-limited 
progenitor, which could both give rise to luminal epithelial and myoepithelial cells, 
either in ducts or in lobules. The question about the stem cell niche also remains still 
to be clarified, together with the identity and location of the stem cell. The possible 
signals and interactions that might be involved between mammary stem cells and 
their niche have recently been discussed, as compared to systems that are well 
understood like the hematopoietic system and the skin (Tanos and Brisken, 2008). 
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 Interesting results were obtained from studies with Rosa26-lox-STOP-lox-LacZ 
reporter mice that can be used to permanently label and track cells in vivo. When 
crossed with mice carrying a Cre transgene, recombination of the floxed Stop codon 
will occur in Cre expressing cells, and the cells will from that moment on 
continuously express lacZ (β-galactosidase) and can be labeled in blue by X-Gal 
staining. Using a Cre recombinase under a milk protein promoter (WAPCre), which 
is only expressed starting mid-pregnancy in differentiating luminal epithelial cells, a 
population of (blue) WAP expressing cells could be identified that did not undergo 
apoptosis during involution and could still be stained in a parous, non pregnant 
female (Wagner et al., 2002). This population was termed Pi-MECs (for parity-
induced MECs), and the cells were thought to arise during pregnancy and eventually 
even from de-differentiation of a fully committed, secretory cell (Fig. 8, left panel). 
They were shown to serve as progenitors in subsequent pregnancies, contributing to 
both luminal and myoepithelial cells in a second pregnancy (Fig. 8, right panel). In 
transplantation studies it was found that Pi-MECs are self-renewing and form lobule-
limited outgrowths (Booth et al., 2007; Wagner et al., 2002), suggesting they are the 
lobule-limited progenitors. In addition, labeling them with GFP instead of LacZ 
expression, which enabled FACS analysis, showed that the Pi-MECs reside within 
the CD49fhi population of the mammary gland (Matulka et al., 2007). Most 
important, they were finally found to exist in the virgin gland and were shown to be 
responsive to hormonal stimulation (Booth et al., 2007), supporting the hypothesis 
that they could be identical to the ‘lobule-limited progenitors’ proposed by Smith and 
colleagues or to the ‘alveolar progenitor’ or ‘luminal progenitor’ proposed by Rosen, 
Visvader and others. The identification of Pi-MECs in virgin glands led to their 
renaming into ‘parity-identified’ MECs, as they were not generated by pregnancy but 
just labeled by WAPCre expression during pregnancy. Nevertheless it is important to 
be aware of the fact that those cells are partially differentiated (WAP expression) yet 
still pluripotent and surviving involution.  
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adapted from Wagner et al., 2002 
 
Figure 8: Theoretical and experimental model of Pi-MECs. Using genetic labeling with 
WAPCre and a reporter gene (with a floxed STOP codon) it was found that a population 
of partially differentiated cells survive involution (left panel). As the reporter gene is 
permanently activated, those cells can be followed in subsequent pregnancies (day 8 of a 
second pregnancy, right panel), where they contribute to a large extent to newly formed 
ducts and alveoli (A: wholemount, B: histological section) but are essentially absent from 
large ducts (C). 
  
 
 
 
 
 
  
  
 To give a short outlook on the situation in human breast: studies have been 
intensified during the past few years and FACS analysis and new markers have been 
used for human cells (for a recent review on markers used for mouse and human 
mammary epithelial cells see Stingl, 2009). In comparison to the mouse, other 
markers are used for the isolation of potential human mammary stem cells: EpCAM 
(epithelial cell adhesion molecule), MUC1 (a luminal cell-specific glycogen), 
ALDH1 (aldehyde dehydrogenase 1) and also CD49f. Testing cell populations in 
transplantation assays suggested that mammary stem cells show a 
EpCAMlowCD49fhiMUC1-ALDH1+ phenotype, implying that their position is basal, 
as also suggested for mouse. A proposed hierarchy for mouse and human mammary 
stem cells based on surface markers can be found in (Stingl, 2009).  
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  1.6 breast cancer   
 One reason to study mammary gland is not only to gain insight into the pathways 
regulating its function and development, but also to understand the mechanisms 
leading to breast cancer and ultimately to find new treatments for this disease. This 
section gives a short introduction to breast cancer, concentrating on the different sup-
types and the available treatments.   
  
  1.6.1   incidence of breast cancer and molecular subtypes 
 Breast cancer is the most common cancer in women worldwide and the most 
important cause of neoplastic deaths among women (World Cancer Report (WCR) 
2008). The incidence is especially high in North America but also in Northern and 
Western Europe (Fig. 9), with high rates of 80-90 per 100,000. Alone in Switzerland, 
over 5,000 women are diagnosed yearly (average from 2001 to 2005) with breast 
cancer, which comprises almost 15% of all new cancers and 32% of all cancers in 
women per year. In addition, breast cancer shows the highest cancer mortality (1,300 
per year), with 1 out of 5 cases (in women) of cancer deaths being caused by breast 
cancer (Source: Krebsliga Schweiz, 2008). Some good news is, that although the 
incidence for breast cancer is increasing, mortality is slowly decreasing, which is 
mainly due to better screening and treatment options (WCR 2008).  
 
 
 
 
  
 
 
 
 
 
 
              
 
from: World Cancer Report 2008 
 
Figure 9: Worldwide incidence of breast cancer. The map refers to women of all ages, 
incidence is given as numbers per 100,000. Note the high incidence in Western Europe.  
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 Breast cancer is a very heterogeneous disease, which in the past was mainly 
diagnosed and described using multiple histological features (such as 
immunohistochemistry (IHC) status of certain markers, proliferation etc.) and light 
microscopy. Over 80% of neoplasms in the breast arise from ductal rather than 
lobular epithelium (WCR 2008) and these roughly are described as atypical ductal 
hyperplasia, intraductal carcinoma (or ductal carcinoma in situ, DCIS) and invasive 
ductal carcinoma (histological classification can be found in a Review from            
Andrew Fischer on the ‘Biology of the Mammary Gland’ webpage, see 
http://mammary.nih.gov/reviews/tumorigenesis/Fischer001/index.html). 
Furthermore, tumors were characterized by expression of steroid and GF receptors, 
such as ERα or ErbB2, by their lymph node status, and histological grade 
(differentiation status). At the beginning of the 21st century, new results from 
microarray analysis allowed the identification of robust subtypes that were defined by 
gene expression, termed ‘molecular portraits’ of breast cancer (Perou et al., 2000; 
Sorlie et al., 2001). Interestingly, those subtypes are further characterized by other 
clinical markers, such as ERα or ErbB2 expression, which led to the following 
nomenclature (Fig. 10A): ‘basal-like’ (showing highest expression of basal keratins 
5, 6, 17 and/or laminin), ‘ErbB2+’ (overexpression of ErbB2), ‘normal breast-like’ (a 
gene expression similar to normal breast samples) and ‘luminal’ (expressing luminal 
keratins 8/18 and being positive for ERα). The luminal, ER+ subtype can be further 
divided into luminal A (showing the highest ER expression), and luminal B and C 
(often combined, showing low to mediate ER expression, luminal C showing some 
similarity to basal-like and ErbB2 subtypes). Importantly, when applying these 
subtype division to a group of 49 breast cancer patients with uniform treatment, a 
clear correlation with clinical outcome was found (Fig. 10B), in which the luminal A 
subtype showed the best, and the basal subtype the worst overall survival (Sorlie et 
al., 2001). The basal subtype is sometimes also called ‘triple negative’, as it is 
negative for expression of ErbB2, ER and PR. Interestingly, tumors with BRCA1 
mutations predominantly fall into this subtype, and are associated with poor 
prognosis (Sorlie et al., 2003). When including results from more recent studies, it 
emerged that 5 subtypes are repeatedly observed, excluding the luminal C (Hu et al., 
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2006). More about c-Myc and the different subtypes of breast cancer can be found in 
chapter V.        
 
 
 
 
 
 
 
 
  
 
 
 
  1.6.2   strategies for treatment of breast cancer 
 Before the detailed analysis of breast cancers by gene expression, mostly IHC (or 
in situ hybridization, FISH) was used to check for expression of certain markers that 
would allow selection of a specific treatment as opposed to normal chemotherapy. As 
such, ER and ErbB2 were the first two markers/molecules against which specific 
therapy for a pre-selected group of patients was available.   
 The ‘oldest’ available targeted therapy for ERα positive breast tumors is the anti-
estrogen or SERM (selective estrogen-receptor modulator) tamoxifen, which was 
synthesized in 1966 in Great Britain, and approved for treatment of metastatic breast 
cancer in 1973 (Great Britain) and 1977 (United States) (Jaiyesimi et al., 1995). Its 
mechanism of action was unsolved for a long time, but it is now clear that tamoxifen 
acts as an estrogen antagonist (recruiting corepressors to the ER) in the breast, while 
it acts as an agonist of estrogen signaling (recruiting coactivators) in other tissues like 
the endometrium (Riggs and Hartmann, 2003). While tamoxifen was the ‘gold 
standard’ of treatment of ER+ tumors for many years, resistance against endocrine 
therapy usually develops. The mechanisms contributing to resistance include a 
‘positive feedback’ crosstalk between ER and GF receptor which enhances the 
 
 
adapted from Sorlie et al., 2001 
 
Figure 10: Molecular subtypes of breast cancer. Gene expression analysis allowed 
clustering of breast tumors into at least 5 subtypes (panel A) with different molecular 
features. In addition, 49 patients separated according to the 5 subtypes (joined Lum B+C) 
showed different clinical outcome (overall survival) when treated uniformly (panel B).  
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agonistic effects of tamoxifen and thus tumor growth (numerous reviews available 
about endocrine resistance, see e.g. Clarke et al., 2003; Osborne et al., 2005). An 
alternative treatment strategy is provided by aromatase inhibitors such as letrozole, 
which block ER signaling by preventing estrogen synthesis (Carpenter and Miller, 
2005). Together with tamoxifen, they form the base for current treatment in the 
metastatic as well as the adjuvant setting (Harichand-Herdt et al., 2009). 
 Amplification of ERBB2 is found in approximately 20-25% of primary breast 
tumors and was the first consistent alteration correlated with breast cancer (Berger et 
al., 1988; Slamon et al., 1987). To date, two different successful treatments are 
available to patients with ErbB2-overexpressing breast cancer: antibodies, targeting 
the extracellular domain of the receptor and TKIs (tyrosine kinase inhibitors) that 
inhibit the intracellular kinase activity (recently reviewed in Hynes and MacDonald, 
2009). The monoclonal antibody trastuzumab (Herceptin) was approved in 1998 for 
treatment of metastatic ErbB2+ breast cancer and has since then developed to an 
important therapeutic option also in the adjuvant setting (for a detailed review of 
trastuzumab history see Ross et al., 2009). The second class of inhibitors includes 
lapatinip, which is a dual EGFR/ErbB2 TKI. One big problem that remains is the 
resistance that can develop in response to therapy, which in the case of ErbB2 
overexpressing breast tumors often seems to involve activation of PI3K/Akt signaling 
pathways (Hynes and MacDonald, 2009). Thus, there is a constant need for new 
targets, new drugs and new combinations of treatments. A variety of promising 
compounds targeting ErbB2 is in Phase I and II clinical trials; alternative strategies to 
enhance anti-ErbB2 therapies have already made it into Phase II and III, like 
targeting Src or VEGF, respectively (Bedard et al., 2009).   
 The use of gene expression analysis to classify and characterize breast tumors has 
opened the door for new and tailored therapies. By identifying activated pathways 
and molecules, specific inhibitors (or combinations of inhibitors) can be directed 
against specifically upregulated or activated targets. This is of special interest in the 
case of the basal breast cancer subtype as no targeted inhibitor like tamoxifen or 
trastuzumab can be used for treatment. Very recently, a study used gene expression 
analysis to identify pathway activation among different subtypes and to predict 
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sensitivity to chemotherapeutic agents (Bild et al., 2009). The results demonstrate 
that a large fraction of the basal subtype exhibits EGFR pathway activation, with an 
inverse pattern of Ras or Src pathway activation. Similarly, there was a big 
heterogeneity within this subtype in gene expression in response to chemotherapy, 
identifying clear clusters that would be sensitive to one agent but resistant to another. 
There is clearly still a big demand for new drugs, but the recent advances in 
technologies are a reason to hope that understanding and treating breast cancer will 
be even more successful in the future. 
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II.  The multiple roles of c-Myc 
 
 The proto-oncogene c-MYC is the most extensively studied member of the myc 
family of oncogenes (which consists furthermore of N-Myc and L-Myc). c-MYC was 
first discovered as the cellular homologue of the transforming sequence of an avian 
virus, which was named myc, for myelocytomatosis (reviewed in Varmus, 1984). 
Interest and research investigations in Myc grew tremendously when it was 
subsequently found to be overexpressed in Burkitt’s lymphoma and various other 
human malignancies (for a recent timeline on Myc in cancer research see Meyer and 
Penn, 2008). This section will try to give an overview on Myc in general, its 
regulation, its connection in signaling networks, and its biological functions. For a 
more detailed description, the reader is kindly referred to PubMed, where to date 
more than 20,000 articles can be found on Myc.  
 
 2.1 structure and regulation  
 Myc expression is regulated by many signals on multiple levels, from 
transcriptional/post-transcriptional to translational/post-translational, with a very 
short half life for mRNA and protein (20-30 min). The levels of c-Myc mRNA and 
protein are usually low in normal cells so that already small changes can exert a big 
effect. This part will focus on the tight and fast regulation of Myc transcription, as 
well as protein modifications influencing its activity or stability.  
 The human c-MYC gene which is located on 8q24 harbors four different 
promoters (P0 to P3, of which P2 is the preferential one for 75 - 90% of transcripts) 
(Wierstra and Alves, 2008). The c-Myc promoters are so complex with containing 
binding sites for such a large number of TFs, GFs or other factors that a recent review 
used 220 pages to describe the current knowledge about the Myc promoters (Wierstra 
and Alves, 2008). To mention only a few, the c-Myc promoter region contains TF 
binding sites for Myc (autosuppression), β-catenin/TCF, Notch/Cbf1, TGFβ/Smads, 
Fos/Jun, E2F, Stat3 and NF-κB. Furthermore, and especially interesting in the 
mammary gland, the c-Myc promoter region was shown to contain an estrogen as 
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adapted from Cole and Cowling, 2008; Ponzielli et al., 2005 
 
Figure 11: Protein structure of c-Myc. The c-Myc protein contains 4 Myc boxes (I - IV), 
a nuclear localization sequence (NLS) and the basic (B) helix-loop-helix (HLH) leucine 
zipper (LZ) motif. Further explanation in the text.  
well as a progesterone responsive element (ERE, Carroll et al., 2006; and PRE, 
Moore et al., 1997). Finally, various signaling pathways influence c-Myc expression, 
leading to a sharp increase upon proliferation stimuli, which can be GFs, mitogens, 
cytokines, hormones, vitamins and other ligands.  
 Before discussing post-translational modifications of the c-Myc protein, its 
structure shall be discussed. Translation of the c-Myc protein can start from two 
alternative translational start sites (Wierstra and Alves, 2008). This generates the two 
major proteins c-Myc1 (p67, starting from the CTG codon) and c-Myc2 (p64, starting 
from the AUG codon), with the latter being the predominant form in growing cells. 
The full-length c-Myc protein contains 2 domains: the N-terminal domain (NTD) and 
the C-terminal domain (CTD, Fig. 11). The NTD is also called transactivation 
domain because it is the major regulatory region necessary for all transactivating and 
transrepressing activities. It contains three conserved motifs known as Myc boxes 
(MBI - III), of which MBII was shown to be the highest conserved motif and the 
most essential for c-Myc’s biological functions and for cofactor binding (Cole and 
Cowling, 2008; Ponzielli et al., 2005).  
 
 
  
 
 
 
 The CTD, also termed DNA-binding domain, contains another Myc box (MBIV), 
the primary nuclear localization signal (NLS) and the essential basic motif (B) for 
binding to the E-box DNA sequence (CACGTG). In addition, it contains the helix-
loop-helix leucine zipper (HLH-LZ) domain, which puts Myc into the superfamily of 
B-HLH-LZ TFs, and which is required for heterodimerization with its binding 
partner Max (Max will be discussed in the next chapter). It was shown that via ‘leaky 
scanning’ mechanism translation may start from alternative downstream AUG 
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codons and produce different truncated (‘small’) forms termed c-MycS (Spotts et al., 
1997). As this form is N-terminally truncated (lacking MBI), it can still 
heterodimerize with Max, but has no transactivating function. 
 The Myc protein is regulated by various post-translational modifications 
including phosphorylation, acetylation and ubiquitinylation (reviewed in Vervoorts et 
al., 2006). Two important phosphorylation sites lie within MBI, Thr-58 and Ser-62, 
which are regulated by PI3K and Ras signaling, respectively. Phosphorylation of Ser-
62 upon activated Ras/MAPK signaling leads to stabilization of c-Myc and 
eventually to effects on Myc-dependent gene expression. In contrast, phosphorylation 
of Thr-58 by GSK3 induces a series of events resulting in Myc degradation. 
Importantly, GSK3 is inhibited by PI3K/Akt signaling, and phosphorylation of Thr-
58 needs phospho-Ser-62 as a prerequisite, thus providing a tight regulation of Myc 
function and half life. Moreover, c-Myc is subject to control by different ubiquitin-
ligase complexes, which are dependent or independent of its phosphorylation status. 
Different ubiquitinylations can have transcription activating effects before actually 
leading to degradation of the Myc protein. Finally, c-Myc is a substrate for several 
histone acetyltransferases that it recruits leading to acetylation at several different 
lysines. The function of acetylation is not yet fully understood, but it is thought to be 
stabilizing, as it might interfere with ubiquitination of lysines.          
 
 2.2 the Myc/Max/Mad transcriptional network  
 c-Myc is only one of a large number of B-HLH TFs that form different dimers 
and act as positive or negative regulators of polymerase (Pol) II mediated 
transcription, depending on the cellular context. The central player of the network is 
Max (Myc associated protein X), as it can form either homodimers or heterodimers, 
depending on availability of dimerization partners, with Myc but also with Mnt, the 
Mxd proteins (formerly called Mad proteins) and Mga (Grandori et al., 2000; Hooker 
and Hurlin, 2006). All complexes bind to E-boxes (see above), but by recruitment of 
different cofactors they exert different effects on transcription (with Max-Max 
homodimers having no transcriptional activity). The network is tightly regulated (and 
well studied) during cell cycle progression, where the levels of its components 
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adapted from Hooker and Hurlin, 2006 
 
Figure 12: The main components of the Myc-Max network. Depending on the binding 
partner, heterodimers with Max will repress or stimulate various target genes.   
change, and gets deregulated in a tumor setting if one of the components is strongly 
upregulated or lost. A simplified scheme of the network is shown in Figure 12. 
 
 
  
 
 
 
 As mentioned above, Max is the central player of the network. Under 
physiological conditions, Max protein shows a very slow turn over, and it seems to 
be expressed at rather constant levels during the cell cycle. The same is true for Mnt, 
which led to a model where Mnt-Max complexes might form a ‘ground state’ and 
repress target gene expression (Hooker and Hurlin, 2006; Hurlin and Huang, 2006). 
c-Myc, which is highly upregulated in response to mitogens at the entry into the cell 
cycle, replaces Mnt and forms complexes with Max, thereby activating transcription 
of multiple targets (discussed below). Although Mnt-Max and Myc-Max complexes 
have been shown to coexist in a variety of proliferating cell types, Max is not very 
abundant and might be limiting in certain settings, especially when dimerization 
partners are expressed at very high levels. Interestingly when looking at 
tumorigenesis, particularly loss of Mnt can result in phenotypes that resemble Myc 
overexpression (e.g. in mammary glands), showing indeed their antagonistic 
competition for Max binding (Hurlin et al., 2003; Nilsson et al., 2004; Toyo-oka et 
al., 2006). As cell cycle progresses, c-Myc levels go down, and levels of Mxd (Mad) 
proteins, which correlate with terminal differentiation, rise and they form complexes 
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with Max, again repressing target gene transcription (Grandori et al., 2000; Hooker 
and Hurlin, 2006). The transcriptional activities involving c-Myc will now be 
discussed in more detail.  
 
  2.2.1   activation and repression of polymerase II targets 
 Myc-Max heterodimers bind to canonical (CACGTG) but also non-canonical E-
boxes. A number of studies have been devoted to identifying and confirming c-Myc-
binding sites and transcriptional targets. To summarize, these studies suggest that c-
Myc binds 15% of all genes (around 25,000 binding sites in the genome!) (for 
reviews see Adhikary and Eilers, 2005; Eilers and Eisenman, 2008; Patel et al., 
2004). One interesting finding was that c-Myc binding takes place almost exclusively 
in a certain chromatin context termed euchromatic islands which contain active 
histone modification marks that are characteristic for actively transcribed or 
previously transcribed loci (Guccione et al., 2006). This widespread DNA binding 
can be controlled and modulated by low protein levels and rapid turnover of c-Myc, 
which implies that c-Myc binding at certain sites is transient and also the exchange of 
cofactors can take place rapidly (discussed in Eilers and Eisenman, 2008). The 
cofactors recruited by c-Myc for transcriptional activation are also numerous and 
include deubiquitinating and demethylating enzymes, histone acetyltransferases and 
other histone modifying proteins (Eilers and Eisenman, 2008). One cofactor that was 
shown to be essential for c-Myc mediated transformation is the adaptor protein 
TRRAP (TRansactivation/tRansformation Associated Protein; Cowling and Cole, 
2006). 
  Moving on to the transcriptional targets of c-Myc, it is a fact that c-Myc acts as a 
relatively weak activator with an average expression change of 2-fold of its target 
genes. Nevertheless c-Myc affects multiple cellular functions due to the large number 
of targets. A list of direct genomic targets, mostly derived from studies in Burkitt’s 
lymphoma, rat fibroblasts and Drosophila, can be found at http://www.myc-cancer-
gene.org/index.asp (Zeller et al., 2003), which to date contains almost 1700 targets. 
When distributing the targets according to functional categories it becomes clear that 
c-Myc affects specific classes of genes from cell cycle regulation, metabolism, 
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protein biosynthesis and cell adhesion/cytoskeleton (Dang et al., 2006). More 
recently, also the miRNA cluster miRNA-17-92 was shown to be upregulated by c-
Myc (O'Donnell et al., 2005). Deregulation of c-Myc furthermore affects apoptosis, 
differentiation, angiogenesis and genomic instability (Meyer and Penn, 2008; 
Ponzielli et al., 2005).  
  As mentioned above (Fig. 10), transcription is also negatively regulated by the 
Myc/Max/Mad network. Mnt, Mxd and Mga in complex with Max compete with 
Myc-Max for binding to the same E-boxes. Repression of transcription occurs via 
recruitment of the SIN3 adaptor protein and histone deacetylases (Adhikary and 
Eilers, 2005). Myc-Max complexes can also repress transcription; indeed, 10 - 25% 
of the identified c-Myc targets are repressed rather than activated (Zeller et al., 2003). 
Repression does not occur via DNA binding, but rather via interaction with, and 
inhibition of, other transcriptional regulators, like Sp1, Smad2/Smad3 and Miz-1 
(Myc-interacting zinc finger protein 1; Eilers and Eisenman, 2008). The well studied 
Cdk-inhibitors p15INK4b (Seoane et al., 2001) and p21CIP1 (Wu et al., 2003) were 
shown to be repressed by c-Myc via interaction with Miz-1 on core promoters. This 
binding has two effects: passive interference with the interaction between Miz-1 and 
coactivators and active recruitment of corepressors (such as DNA methyltransferase) 
to Miz1 (Brenner et al., 2005). Another recent study showed that in contrast to the 
miRNA-17-92 cluster, c-Myc represses a large number of other miRNAs, including 
members of the let7 family (Chang et al., 2008). A summary of Myc’s transcriptional 
activity is shown in Figure 13. 
 
   
 
 
 
 
 
 
 
Introduction: c-Myc 
 
 - 33 - 
           
 
Figure 13: Schematic overview of transcriptional c-Myc targets. Information and 
examples found at http://www.myc-cancer-gene.org/index.asp (Zeller et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2.2.2   activation of transcription by Pol I & III 
  In addition to the large number of Pol II transcribed targets, another interesting 
aspect is that c-Myc also regulates transcription by Pol I and Pol III (Fig. 13), thus 
linking cell growth and metabolism to cell division (reviewed in Oskarsson and 
Trumpp, 2005). Pol I transcribes the rRNA gene to produce a 45S eukaryotic pre-
rRNA precursor, which gets further processed into the 18S, 5.8S and 28S rRNA. c-
Myc was shown to directly activate rRNA transcription via binding of several E-
boxes in the promoter region and recruitment of TRRAP (Arabi et al., 2005; Grandori 
et al., 2005), similarly to what was shown for activation of Pol II driven transcription. 
In contrast, activation of Pol III transcription occurs via a different mechanism. The 
Pol III transcribed genes for tRNA and 5S rRNA do not contain a DNA sequence that 
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is directly recognized by c-Myc. It was shown that c-Myc activates Pol III 
transcription by interaction with the Pol III specific factor TFIIIB (Gomez-Roman et 
al., 2003), involving recruitment of TRRAP and histone acetyltransferases (Kenneth 
et al., 2007). Together with Pol II transcribed targets like ribosomal proteins, 
translation factors and rRNA processing factors, this makes c-Myc a master regulator 
of protein synthesis (White, 2005).   
  
  2.3 other functions of c-Myc 
  Recently, other functions of c-Myc have been described that do not result in 
transcriptional changes of single targets but affect other cellular aspects. In addition 
to changing histone modifications to activate target gene transcription, it was shown 
that c-Myc (and also N-Myc) acts as a global regulator of chromatin (Knoepfler et 
al., 2006). In this study, loss of Myc resulted in a decrease in active and an increase 
in repressive chromatin marks and expanded heterochromatic regions. This was 
mechanistically explained by lower levels of the histone acetyltransferase GCN5, a 
likely Myc target gene. Another function of c-Myc with a very broad effect is the 
ability to regulate DNA replication. It was shown that independent of its 
transcriptional activity, c-Myc binds to the pre-replicative complex and increases 
activity at DNA replication origins (Dominguez-Sola et al., 2007). The authors 
further speculate that this is not only another mechanism for c-Myc to drive 
proliferation but also a way how deregulated c-Myc may promote DNA damage and 
genomic instability by inducing DNA replication stress. Finally, c-Myc was found to 
influence translation of target genes and non-target genes via two different 
mechanisms (reviewed in Cole and Cowling, 2008). First, c-Myc induced global 
(target gene independent) phosphorylation of the C-terminal domain of Pol II, which 
is necessary to release the paused Pol II and drive elongation of transcription 
(Cowling and Cole, 2007). This study further showed that c-Myc increased mRNA 
5’-cap methylation of target but also non-target genes, which led to increased 
polysomal loading of those mRNAs and increased translation rate. Interestingly, the 
same group showed this year that cap methylation occurred very frequently for c-
Myc targets while being absent from control genes like GAPDH, and that the 
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increase in cap methylation (from 1.5- to 8.9-fold) was usually higher than 
transcriptional upregulation (from 1.4- to 2.2-fold) (Cole and Cowling, 2009). This 
finding led to the new hypothesis that mRNA cap methylation might even be the 
major mechanism underlying c-Myc regulation of gene expression.  
 
 2.4 c-Myc in human cancer 
 Studies on c-Myc in human malignancies started in the early 1980s, when c-MYC 
was found to be the human cellular homologue of the transforming sequence of the 
avian myelocytomatosis retrovirus MC29 (recently reviewed in Meyer and Penn, 
2008). It was an interesting finding that in contrast to other oncogenes like Ras, c-Myc 
seemed not to be generally activated via mutations in the coding sequence, but rather 
by other mechanisms. Two mechanisms identified for c-Myc were insertional 
mutagenesis, where c-Myc was activated by viral promoter insertion (Hayward et al., 
1981; Payne et al., 1982), and translocation, where the c-MYC locus is translocated to 
Ig heavy and light chain genes, the dominating deregulation found in Burkitt’s 
lymphoma (Dalla-Favera et al., 1982). In solid tumors, aberrant levels of c-Myc are 
obtained via amplification or overexpression and occur with high frequency in many 
tumor types (a table of Myc deregulations in human tumors can be found in Vita and 
Henriksson, 2006). As c-Myc itself is a target of numerous signaling pathways, TFs, 
hormones etc. (see above), its overexpression can occur on various different levels and 
thus is a likely event in any human cancer: c-MYC mRNA expression gets enhanced via 
activated GFs, receptors or hormones (e.g. EGF, Wnt, E), via activated second 
messengers (e.g. Src, Ras, Akt) and via activated TFs (e.g. Notch, β-catenin/TCF) 
(Meyer and Penn, 2008). Furthermore, factors influencing Myc mRNA and protein 
stability and turnover can be deregulated in cancer and thus change Myc protein levels. 
Some examples of mechanisms that occur in breast cancer are discussed in Chapter V.   
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III. Studying c-Myc function in mouse models 
  
  This section will describe various in vivo studies that have helped to clarify many 
different functions of c-Myc not only during embryogenesis, organ development and 
homeostasis, but also in tumorigenesis. For the mammary gland, different transgenic 
overexpression models exist, which are described in the first part of this section; 
however, there is not a lot known about the effects of c-Myc loss in this organ. In 
contrast, in many other organs like bone marrow, intestines and skin, conditional KO 
(CKO) of c-Myc has been performed, and this will be discussed in the second part of 
the section. Finally, c-Myc has also been tested as a tumor target in mice, via genetic 
downregulation or chemical treatment, which is summarized in the last part of the 
section.    
 
  3.1 c-Myc overexpression in the mammary gland using 
transgenic mouse models  
  3.1.1   tumorigenic phenotypes 
  As c-Myc is known to play a role in development and progression of many human 
cancers, including breast cancer, it has been widely studied in different transgenic 
mouse models (reviewed in Jamerson et al., 2004). The first transgenic model 
generated was c-Myc expression under the mouse mammary tumor virus (MMTV) 
promoter (Stewart et al., 1984). This regulatory element shows activity in mammary 
epithelium of virgin mice and is greatly enhanced by hormones during pregnancy 
(Donehower et al., 1981). In this study, the incidence of mammary adenocarcinomas 
was 100% for multiparous and around 50% for virgin animals. The fact that the 
tumors arose spontaneously and not uniformly in all mammary glands suggested that 
c-Myc overexpression alone was not sufficient for transformation in vivo (Stewart et 
al., 1984). Another transgenic model utilized the WAP promoter, where transgene 
expression is low during each estrus cycle and high in secretory alveolar cells during 
late pregnancy and lactation (Sandgren et al., 1995; Schoenenberger et al., 1988). As 
expected from the expression pattern of the WAP promoter, both studies reported that 
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pregnancy/lactation was indispensable for tumor formation (80 – 100% incidence in 
multiparous females) and virgin animals stayed tumor free during 4 months. 
Interestingly, the tumors showed constitutive milk protein expression of WAP-Myc 
as well as endogenous WAP and β-casein, independently of lactation 
(Schoenenberger et al., 1988). Recently, new insights were gained from an inducible 
tetracycline-dependent model, where c-Myc expression in mammary and salivary 
gland can be induced at any time by giving doxycycline to the mice (MMTV-
rtTA/TetO-Myc; Boxer et al., 2004; D'Cruz et al., 2001). Induction of transgene 
expression led to tumor formation with high incidence (86% after 22 weeks) as well 
as rapid regression in around 50% of tumors within 2 weeks after doxycycline 
removal. Interestingly, many of the non-regressing tumors as well as some of the 
relapsing tumors displayed activating mutations in Kras2 or Nras. Thus, mutant Ras 
seems to facilitate an escape from Myc dependence in Myc-induced breast tumors, 
which is in contrast to most other Myc-induced tumors, that fully regress upon Myc 
inactivation (reviewed in Arvanitis and Felsher, 2006). The synergy between 
MMTV/WAP-c-Myc and other oncogenes was also examined in various bitransgenic 
models (reviewed in Jamerson et al., 2004), using for example activated Ras or Neu 
and thereby greatly accelerating tumor formation. 
   
  3.1.2 non-tumorigenic phenotypes 
  The above mentioned doxycycline inducible model (D'Cruz et al., 2001) was 
further used to investigate non-tumorigenic effects of  aberrant c-Myc expression at 
different times in mammary gland development. Expression of c-Myc was shown to 
be tightly regulated in the mammary gland, being high during early pregnancy, 
almost undetectable during lactation and upregulated again in involution (Master et 
al., 2002; Strange et al., 1992). Two studies used the inducible transgenic model to 
describe effects of c-Myc overexpression during pregnancy (Blakely et al., 2005) and 
involution (Sutherland et al., 2006). To date, these are the only non-tumorigenic Myc 
studies in the adult mammary gland, thus they will be discussed in more detail. 
  CKO studies have shown how the effects of c-Myc depend to large extent on the 
time when the deletion occurred. Microarray data revealed that c-Myc expression in 
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the mammary gland rises nearly 3-fold from virgin until day 6 of pregnancy, reaches 
basal levels again by day 18 of pregnancy, and is 3- to 4-fold downregulated during 
lactation. The Chodosh lab found that a very short c-Myc induction from day 12.5 to 
day 15.5 of pregnancy is necessary and sufficient to result in complete pup death 
within 24h after birth. The lactation failure was found to result from precocious 
lactogenic development leading to apoptosis even before parturition. As a primary 
effect only 24h after c-Myc induction, the proliferation rate of mammary epithelial 
cells was induced 10-fold, followed by premature activation of Stat5 and high 
expression of milk proteins. Mechanistically, this was explained by a rapid 
downregulation of Cav1, which is a target of transcriptional repression by c-Myc 
(Park et al., 2001) and a negative regulator of the Prl-Jak2-Stat5 pathway (Park et al., 
2002). Interestingly, aberrant c-Myc expression also induced high epithelial apoptosis 
within 24h after doxycycline treatment and a second wave of apoptosis later in 
pregnancy. This second phase was caused by milk stasis and directly led to 
precocious involution via activation of Stat3 and Tgfβ3 pathways. This study brought 
some insight into the effects of specific and restricted overexpression of c-Myc in the 
mammary gland, including some interesting potential targets and the finding that 
overall proliferation and differentiation were accelerated by abnormal c-Myc levels.    
  The second study, published by the Visvader lab, utilized the inducible c-Myc 
model to address the role of c-Myc in involution. They initially investigated 
conditional Socs3 KO mice (WAPiCre;Socs3-/fl) which undergo precocious 
involution. The mammary glands of these mice display increased Stat3 activation 
during lactation, where it is normally repressed by Socs3, followed by significantly 
elevated levels of the pro-apoptotic regulators Bax and Bak. Interestingly, also c-
Myc, which is a Stat3 target, and the pro-apoptotic c-Myc target genes E2F-1 and 
p53 were found to be upregulated in Socs3-deficient glands. To test whether c-Myc is 
the main mediator of the involution phenotype observed in Socs3 CKO mice, they 
induced c-Myc expression in the transgenic model at day 8 of lactation followed by 
forced involution 2 days later (and continuing doxycycline treatment for 2 more 
days). Following 4 days of c-Myc induction, involution was found to be dramatically 
accelerated, including increased apoptosis and elevated levels of Bax, p53 and E2F-1. 
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These results show that c-Myc has a clear role in involution, at least from 
overexpression studies.  
 
  3.2 c-Myc downregulation in various systems 
  3.2.1 full knockout: embryonic lethality and partial rescue 
  Starting in the 1990s, an increasing number of reports investigated not only 
tumorigenic functions of c-Myc, but focused on its physiological roles in 
embryogenesis and development. The first attempt to create homozygous KO mice 
revealed that a c-myc null mutation is embryonic lethal between 9.5 and 10.5 days of 
gestation (Davis et al., 1993). Homozygous embryos analyzed before that showed a 
strong general delay in development as well as a reduction in size and other 
abnormalities. Interestingly, also adult females heterozygous for the null allele 
revealed a phenotype, namely reduced fertility. However, the primary defect caused 
by c-myc loss was not determined in this report. In 2001, a series of mice with 
stepwise decreasing c-Myc levels was published, including a new null allele and a 
floxed allele (Trumpp et al., 2001). This study confirmed the embryonic lethality of 
complete c-Myc loss and showed further that incremental reduction of c-Myc levels 
lead to incremental decrease in body mass. Mice heterozygous for the c-myc null 
allele never reached the size of normal littermates with all organs being reduced in 
size as well. Using flow cytometry it was found that not cell size but cell number was 
reduced in most organs, in contrast to Drosophila dmyc mutants, which are smaller 
due to hypotrophy (Johnston et al., 1999). The discussion whether c-Myc affects cell 
number and/or cell size will appear also in other c-Myc CKO studies. The c-mycfl/fl 
mice generated in 2001 (de Alboran et al., 2001; Trumpp et al., 2001) were intensely 
studied using transgenic mice carrying Cre recombinase under various promoters for 
organ specific Myc deletion (for examples, see below). Recently, by using a Sox2-
Cre recombinase, which leads to c-Myc loss specifically in the epiblast, it was shown 
that the observed embryonic lethality was due to the indispensable requirement of c-
Myc in the placenta and the hematopoietic system (Dubois et al., 2008; He et al., 
2008). Most other non-hematopoietic tissues were able to proliferate and develop 
even in the absence of c-Myc, until the embryos died before day 12 of gestation due 
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to severe anemia. The specifically important role of c-Myc in the hematopoietic 
system was investigated in great detail, which will be discussed in the next section.   
 
  3.2.2 conditional knockout in the hematopoietic system 
  As mentioned above, c-Myc plays a pivotal role in the fetal hematopoietic 
development. Although definitive hematopoietic stem cells (HSCs) were generated, 
they were non-functional and unable to expand in vitro or in vivo in mutant liver 
(Dubois et al., 2008). While expression of adhesion molecules was not altered and 
migration to the liver seemed not affected, p21CIP1 was found to be upregulated in 
mutant stem/progenitor cells. A different mechanism for c-Myc was found in adult 
HSCs (Baena et al., 2007; Wilson et al., 2004). Deleting c-myc perinatally in liver, 
spleen and bone marrow (using the IFNα-inducible Mx-Cre transgene) leads to 
severe anemia and loss of committed hematopoietic lineages, while HSCs are 
accumulating in the bone marrow. While Baena et al. reported overexpression of both 
p21CIP1 and N-Myc in one subset of HSCs, Wilson et al. found a striking upregulation 
of adhesion molecules in another subset. They proposed a model where loss of c-Myc 
in HSCs does not impair their self-renewal and proliferative capacity, but due to high 
expression of adhesion molecules the cells cannot leave the stem cell niche and fail to 
differentiate. Supporting this model was also the finding that c-Myc-deficient HSCs 
were fully able to differentiate ex vivo, albeit with only minimal expansion in the 
transient amplifying cells. Recently, it was shown that N-Myc plays a major role in c-
Myc-deficient bone marrow (Laurenti et al., 2008). While loss of N-Myc alone did 
not affect HSCs, simultaneous deletion of c- and N-Myc led to a rapid depletion of 
the HSC pool due to aberrant proliferation and increased apoptosis. This is one 
example of how N-Myc can at least in part functionally replace c-Myc in vivo. 
 
  3.2.3 conditional knockout in the intestines 
  The intestinal epithelium is a well organized, highly regenerating epithelium, 
where stem cell proliferation and differentiation are coupled to migration within the 
intestinal units called crypts (Sancho et al., 2003). As c-Myc is a well established 
target of the Wnt/β-catenin pathway in intestinal crypts (van de Wetering et al., 
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2002), two groups investigated the effects of c-Myc loss in this organ using different 
Cre transgenic mice. Deletion of c-Myc in the small intestine using the Villin 
promoter in 1 week old mice led to a surprisingly mild phenotype, with an early 
transient decrease in crypt number but a complete absence of long-term defects in 
adult intestines (Bettess et al., 2005). In contrast, deletion of c-myc using the Cyp1a 
promoter in 10 week old mice induced a strong selection against c-Myc-deficient 
crypts within less than 4 weeks (Muncan et al., 2006). Interestingly, when 
investigating c-Myc-deficient crypts in more detail, it was found that cell number as 
well as cell size was reduced compared to Myc proficient crypts. By performing an 
AgNor staining (against the silver-stainable proteins of the nucleolar organizing 
regions), it was shown that biosynthetic activity was reduced in c-Myc-deficient 
crypt cells, leading to reduced growth rate and slower cell cycle kinetics. Although 
adhesion molecules and migration were not investigated in this study, it becomes 
clear that the functions of c-Myc greatly depend not only on the cell type but also on 
the developmental stage of the analyzed cell or organ.    
 
  3.2.4 conditional knockouts in other organs   
  Several other CKOs have been described for c-Myc, for example in pancreas 
(Bonal et al., 2008; Nakhai et al., 2008), kidney (Couillard and Trudel, 2009), liver 
(Baena et al., 2005; Li et al., 2006) and skin (Oskarsson et al., 2006; Zanet et al., 
2005). Summarizing those reports one can say that c-Myc loss in vivo often has an 
impact on proliferation, differentiation and apoptosis, variable even within one organ, 
depending on the exact Cre transgene used, but maybe even more on the exact time 
point of induction. Also stem cells are frequently affected in the CKOs, which is 
most obvious during processes of regeneration, wound healing or development, while 
c-Myc seems rather dispensable for adult homeostasis. One example of very 
opposing results from literature can be found for the liver, where cell size and 
regeneration after hepatectomy were affected in one study using juvenile Mx-Cre 
mice (Baena et al., 2005), while another report shows successful proliferation after 
hepatectomy following AdCre vector injection in adult mice (Li et al., 2006). 
Similarly, contradictory results were observed by two groups using the K5-Cre to 
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delete c-Myc from skin. Mice in which the epidermis was c-Myc-deficient from 
embryonic day 14 on showed smaller cell size, decreased proliferation and stem cell 
amplification, leading to fragile skin, hair loss and greatly impaired wound healing 
(Zanet et al., 2005). In contrast, when deleted from skin in 3 weeks old mice, c-Myc 
was not required for homeostasis or chemically (TPA) induced hyperproliferation 
(Oskarsson et al., 2006). This shows how multifaceted and differentially regulated 
the in vivo effects of c-Myc can be.      
 
  3.3 targeting c-Myc in mouse tumorigenesis 
  Apart from the numerous CKO studies to investigate the physiological functions 
of c-Myc, several reports analyzed loss of Myc in non Myc-induced tumor models. 
As c-Myc is frequently elevated in various human malignancies, these reports, which 
are discussed below, give important insights for considering c-Myc as therapeutic 
target in cancer therapy.  
 
  3.3.1  c-Myc in skin tumorigenesis 
  The same study that reported that c-Myc was dispensable for normal skin 
homeostasis also analyzed the effects of c-Myc loss on Ras-driven tumorigenesis 
(Oskarsson et al., 2006). In a first setting, c-Myc CKO (K5-Cre) mice were 
challenged with TPA to induce hyperproliferation, and interestingly no difference 
was found in c-Myc-deficient epidermis. In the second setting, double treatment with 
DMBA/TPA was used, which was shown to produce papillomas harboring one 
activating H-Ras mutation (Quintanilla et al., 1986). It is important to note that Myc 
and Ras were the first known example of oncogene cooperation during cellular 
transformation (Land et al., 1983). Strikingly, the number of DMBA/TPA induced 
papillomas was strongly reduced in mice with c-Myc-deficient skin. Furthermore, it 
was found that none of the tumors grown on mutant skin harbored the c-Myc deleted 
allele, suggesting that the tumors specifically selected ‘escaper cells’ and that c-Myc 
is absolutely required for Ras-driven tumorigenesis. More detailed analysis revealed 
that a key function of c-Myc during epidermal tumorigenesis was the repression of 
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the CDK inhibitor p21CIP1, which was strongly upregulated after c-Myc loss and 
could explain the resistance to papilloma formation. 
 
  3.3.2   c-Myc and the Wnt pathway  
  Apc (adenomatous polyposis coli) is part of the β-catenin destruction complex 
and an important mediator of the canonical Wnt signaling pathway. Mutation or loss 
of Apc leads to stabilization and accumulation of active β-catenin, which is a key 
event of colorectal cancer development (Korinek et al., 1997). As c-Myc is a well 
established transcriptional target of β-catenin/TCF (He et al., 1998), mouse models 
with truncated (ApcMin/+) or downregulated (Apcfl/flAhCre+) Apc were employed to 
address the function of c-Myc on intestinal tumor formation (Sansom et al., 2007; 
Yekkala and Baudino, 2007). It was found that in ApcMin/+c-Myc+/- mice tumor 
incidence was greatly decreased by c-Myc haploinsufficiency, thereby increasing 
survival of the mice (Yekkala and Baudino, 2007). The polyps that formed were 
significantly smaller, which was only in part due to decreased proliferation and 
increased apoptosis, but mostly due to decreased production of angiogenic factors, 
like VEGF. In the Apcfl/flMycfl/flAhCre+ setting, where almost 90% of the intestinal 
crypts were deficient for both genes after 4 days, it was found that loss of c-Myc 
reversed all perturbed phenotypes (proliferation, differentiation, migration) induced 
by Apc deletion (Sansom et al., 2007), while levels of nuclear β-catenin still 
remained high. Interestingly, microarray analysis showed that about 60% of the Wnt 
target genes in the intestines were Myc-dependent. The same Apc mouse model was 
used to study its function in liver, where Apc loss led to high levels of β-catenin and 
c-Myc, high proliferation and hepatomegaly (Reed et al., 2008). Surprisingly, c-Myc 
loss in the liver did not rescue any of the observed phenotypes, while loss of β-
catenin did, highlighting the differences of Myc dependence in the Wnt pathway in 
specific organs.  
 
  3.3.3   whole body targeting of c-Myc in Ras-induced lung carcinomas 
  Another strategy was used to interfere with c-Myc signaling in the whole body, 
which is to interfere with its heterodimerization with Max. This is achieved via 
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expression of Omomyc, a dominant interfering Myc binding partner, that can prevent 
Max binding and Myc dependent transcriptional activation (for detailed analysis see 
Soucek et al., 1998; Soucek et al., 2002). Expression of Omomyc was able to reverse 
Myc-induced transformation in vitro (Soucek et al., 2002) as well as Myc-driven skin 
tumorigenesis in vivo (Soucek et al., 2004). In their latest study, Soucek and 
coworkers created an inducible Omomyc mouse, which expresses Omomyc in 
multiple tissues after administration of doxycycline (Soucek et al., 2008). Using this 
transgenic line, they investigated the function of c-Myc in tumor initiation and 
maintenance of a Kras-driven lung cancer mouse model (expressing the oncogenic 
KrasG12D). Strikingly, interfering with Myc significantly reduced proliferation and 
blocked formation of lesions. When expressing Omomyc for only one week after 6 
weeks of tumor growth, a marked shrinkage of lesions was observed and remaining 
lesions were highly apoptotic. Finally, after 18 weeks of tumor growth when mice 
had developed multiple lesions and some highly vascularized adenocarcinomas, Myc 
interference again induced shrinkage after only 3 days, with significant reduction of 
proliferation after 6 days of Omomyc expression. After 28 days of expression, lungs 
appeared to be free of obvious tumors, showing that Myc function is indispensable 
for all stages of KrasG12D-driven lung tumorigenesis. Importantly, the observed side 
effects during 4 weeks of Omomyc expression were tolerable and general health of 
the mice was not affected. Rapid turning-over organs, like skin, testis and intestines 
that were significantly affected by Myc inhibition, all recovered within one week 
after ending Omomyc expression.     
 
  3.3.4   c-Myc in Notch-induced mammary tumorigenesis 
  Besides the above discussed tumor models in skin, intestines, liver and lung, there 
is one single study investigating the loss of c-Myc in mammary tumorigenesis, 
induced by the constitutively active Notch1 intracellular domain (IC) (Klinakis et al., 
2006). This approach used MMTV-Notch1IC transgenic mice which develop lactation-
dependent regressing and non-regressing tumors that showed increased Myc 
expression as well as high microarray profile similarity with MMTV-Myc induced 
tumors. The MMTV-Notch1IC transgenic mice were further crossed with 
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mycfl/flWapCre mice to analyze whether the upregulated Myc levels in Notch-induced 
tumors were functionally relevant. The authors observed that development of 
regressing tumors was almost completely prevented upon Myc loss, and non-
regressing tumors (observed from 7 to 15 months) showed a highly increased latency 
and a reduced incidence in Myc-deficient mice. In addition, all microlesions or 
eventual tumors that were examined in Myc-deficient mice were shown to stem from 
‘escaper’ cells that had retained Myc, and no recombined allele was detected in any 
of the tumors. The authors concluded from this that Myc is indispensable for Notch-
induced mammary tumorigenesis and further showed that Myc is a direct 
transcriptional target of Notch1. One drawback of this study is that two hormonally 
controlled Cre lines are combined, whose onset cannot be regulated by the 
investigator; thus, the question of Myc function after establishment of the tumor 
could not be addressed in this study. Still, the effect is particularly interesting as the 
authors also detected a correlation between expression of the two genes in patient 
samples of breast carcinomas. Given the large number of signaling pathways that 
mediate directly or indirectly via c-Myc, like Wnt, ER and ErbB2, it will be 
interesting to investigate the impact of Myc loss in cancer models depending on those 
pathways.  
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AIMS OF THE WORK 
 
 c-Myc plays a central role in signaling pathways frequently deregulated in breast 
cancer and might especially gain importance in the basal, poor prognosis subtype, 
where high pathway activation of c-Myc is found. Furthermore, transgenic models 
revealed that c-Myc overexpression affects normal mammary gland development 
during embryogenesis, pregnancy/lactation and involution. However, before this 
study the physiological functions of c-Myc had not been addressed using knockout 
mice. 
 We investigated this open question by using a conditional knockout approach, 
crossing c-mycfl/fl mice to mice heterozygous for the WAPiCre transgene. Thereby we 
wished to identify the phenotype resulting from c-Myc loss during first pregnancy, 
and its effects on subsequent pregnancies. In addition, we aimed at identifying the 
mechanisms behind the observed phenotype(s) by performing different experiments 
with the mammary glands of mutant and wild type mice. When we observed that c-
Myc mutant mice showed a decreased nursing efficiency, we performed detailed 
analysis of mutant milk samples as well as histology of the glands, revealing that 
milk production was reduced in mutant mothers. In order to obtain statistically 
significant results, we carried out image analysis and quantified alveolar versus total 
organ area, using Definiens software. The remaining challenge was to identify the 
targets or pathways that were affected by c-Myc loss, as it is known that c-Myc is a 
very broad, but weak transcriptional regulator of various cellular processes. This was 
accomplished by performing electron microscopy studies and establishing a 
polysome fractionation of mammary gland lysates. Our hypothesis of reduced 
translation efficiency was affirmed by qPCR results showing that components 
involved in ribosome biogenesis and translation were reduced in mutant glands. One 
surprising finding was the differential effect on mRNAs whose protein products are 
involved in milk synthesis, as compared to mRNAs of house keeping genes. Finally, 
we performed a ‘cleared fat pad’ mammary transplantation assay to investigate the 
effect of c-Myc loss on progenitor cells. 
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Additional files 
 
Additional file 1 
File format: PDF 
Title: Additional figure 
Description: Immunohistochemistry for c-Myc. (A) Fetal liver of a day 10.5 embryo 
as positive control [22] showing strong nuclear staining in dark violet (counterstain 
pink). Scale bar, 50 µm. (B) Wild type (WT) and mutant mammary glands at second 
pregnancy day 6.5, when c-Myc expression is highest. WT epithelium shows clear 
dark staining compared with mutant glands, shown in the upper panel in violet (with 
pink counterstain) and in the lower panel in red (no counterstain). Note that in the 
mutant gland (lower panel) some epithelial clusters retained c-Myc (insert b, red 
staining) while all other clusters are clearly Myc-deficient (insert a, no staining). 
Scale bars, 50 µm. 
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Additional file 2 
File format: PDF 
Title: Supplementary methods 
Description: Condition for quantitative polymerase chain reaction (PCR) and all 
primers used in semi-quantitative and quantitative PCR analyses. 
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Stoelzle et al.   Supplementary Methods 
 
Semi-quantitative and qPCR 
Quantitative qPCR was performed using the Absolute SYBR Green ROX Mix 
(Thermo Scientific, Waltham, MA) and 1 µl of cDNA. Relative expression was 
determined in a ABI Prism 7000 cycler (Applied Biosystems Inc., Foster city, CA) in 
duplicate measurements, using β-actin levels as reference. All qPCR reactions were 
performed with the following cycling parameters: 50°C 2 min, 95°C 15 min, 40 
cycles of 95°C 15 sec, 60°C 20 sec, 72°C 1 min.   
 
The following specific primers were used for semi-quantitative or quantitative PCR: 
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aRP: ribosomal protein 
b5’-ETS of the 45S rRNA precursor 
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Figure S1: Mirax slide scanner (left) and Mirax Viewer (right). Easy and automated 
scanning produced perfectly stitched images of whole sections, which could be examined 
with the Mirax Viewer. The viewer allows easy zoom-in up to high magnification (40x).   
Additional data: Image analysis 
 
 One major experimental approach of our study was the automated analysis of 
areas for quantification of alveolar area. It is worth mentioning the analysis process 
in more detail since much effort went into producing the accurate results published in 
the Research Article (Stoelzle et al., 2009). Automated staining of mammary gland 
sections was performed using Ventana Discovery System (program ‘mCC1’) with a 
CK18 antibody (Progen) to stain specifically the epithelium (alveoli and ducts) while 
nuclei (lymph node, stromal cells and epithelium) were counterstained in blue. 
Automated overnight scanning of the sections was done with a Mirax Scan slide 
scanner (Zeiss) that produced high resolution images (around 1 GB per slide) that 
could be viewed and zoomed in with the Mirax Viewer (Fig. S1).  
 
 
 
 
 
 
 Images were exported form the Mirax Viewer into AxioVision in a lower 
resolution to allow image analysis, which was carried out using Image Pro, Image 
Access and Definiens software. The goal of the image analysis was to detect organ 
area, lymph node area and alveolar area (epithelium and lumen), in order to calculate 
the ration of alveolar area over total organ area. A feasibility study performed on one 
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Figure S2: Feasibility study with Definiens. A very detailed detection of different 
categories of areas was obtained on a test slide. Left: original scanned image. Right: 
segmentation performed by Definiens.  
test slide using Definiens promised a high accuracy (Fig. S2) as a detailed detection 
of alveolar epithelium and lumen as well as the other organ components was 
achieved.  
 
   
 
 
 
 
 However, when the large scale analysis was launched, we were confronted with 
different problems in alveolar detection and so that we used Image Pro and Image 
Access as two other approaches to validate the results obtained by Definiens. Two 
major problems that had to be solved with Definiens were the detection of blood 
vessels or other background features as ‘false positive’ alveoli and the detection of 
large alveolar areas as ‘false negative’ background (see Fig. S3). This led to big 
errors in the calculation of alveolar area, which became clear when comparing the 
values to the results obtained from manual quantification. Manual analysis was 
carried out with the ‘Measurement’ option in Image Access and manual ‘drawing’ 
around alveoli on a pen screen. This produced by far the most accurate results; 
however, quantification took between 1 and 6 hours per image, depending on the 
developmental stage of the animal.   
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Figure S3: Problems with Definiens. Automated detection of alveolar and stromal area 
caused big problems when glands were densely filled, like at lactation day 10.5. Due to 
wrong classification, alveolar area for this section resulted in 60% when calculated by 
Definiens (left panel), while manual measurement (right panel) resulted in 80%.   
 
 
   
 
 
 
 
  A very accurate analysis could also be performed with Image Pro, depending on 
the quality of the original image and staining. The analysis was based on a simple 
‘color cube based’ segmentation. By picking a 3x3 or 5x5 pixels color field, alveolar 
epithelium was detected, and closed objects were generated by using the ‘spatial 
filtering’ option. This generated filled objects that could be automatically measured 
(counting and area measurement) and provided us with a relatively easy, fast and 
accurate alternative for area measurement. However, quality of the results was 
strongly depending on the quality of the staining and the developmental stage of the 
mammary gland with the biggest errors also occurring at lactation day 10.5. Only 
long and intense discussions with Definiens could solve all problems according to 
our satisfaction. This required many rounds of trouble-shooting and could only be 
accomplished with the tremendous support of Patrick Schwarb. The final analysis 
carried out by Definiens was highly accurate, could be applied to our large set of 
sections, and the results were completely in the range of manually obtained results. A 
summary of all 3 different methods and a comparison between Definiens and manual 
analysis is shown in Figure S4. 
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Figure S4: Quantification of alveolar area via different methods. (A) ImagePro, (B) 
manual measurement in ImageAccess and (C) automated measurement with Definiens. 
(D) For quality control, various sections of wild type (Wt) and mutant (Mu) glands from 
different time points of pregnancy and lactation were measured manually and values 
compared to the Definiens results. The chart shows the final results of the analysis.  
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 In our study, we describe for the first time effects of c-Myc loss on normal 
mammary gland development using a conditional knockout approach. Our model is 
based on WAPiCre transgenic mice, in which recombination and loss of c-Myc 
specifically occurs in luminal alveolar cells starting in mid-pregnancy. Three major 
phenotypes were observed in c-Myc-deficient glands: first, during early pregnancy 
mutant cells displayed a slower proliferative response, leading to a delayed, but not 
blocked differentiation. Second, polysome fractionation revealed a decreased 
translation efficiency in mutant glands, which was accompanied by lower levels of 
ribosomal proteins and rRNA. This resulted in reduced milk production and slower 
body weight-gain of pups nursed by mutant mothers. Third, in transplantation 
experiments, epithelium from mutant glands showed less ability to repopulate a 
cleared fat pad, suggesting a role for c-Myc in progenitor cells. As this is the first 
study describing a CKO of c-Myc in the mammary gland, it is interesting to compare 
our results with other published reports and to highlight similarities as well as 
differences.    
  
 c-Myc had already been implicated in normal mammary gland development, from 
studies with transgenic mice (see Introduction Chapter V: Hynes and Stoelzle, 2009). 
During embryogenesis, Neuregulin3 (Nrg3) is an important signal for placode 
formation and ectopic expression of Nrg3 in K14-Nrg3 mice led to epidermal 
hyperplasia and formation of additional placodes (Howard, 2008). Interestingly, high 
levels of c-Myc and decreased levels of adhesion proteins were observed in the skin 
of K14-Nrg3 animals, suggesting that Nrg3 might regulate lineage commitment via 
c-Myc, by changing adhesion properties of the cells. In another study, transient 
overexpression of c-Myc from day 12.5 to day 15.5 of pregnancy induced precocious 
proliferation and differentiation (Blakely et al., 2005). The authors showed that this 
effect was due to the ability of c-Myc to downregulate Cav1, a negative regulator of 
the Prl-Jak2-Stat5 signaling. Finally, the third set of data implicating c-Myc in the 
Discussion 
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adapted from Hynes and Stoelzle, 2009 
 
Figure S5: A model summarizing known and speculated functions of c-Myc in the 
mammary gland. The figure shows at which developmental stage which phenotype was 
observed by using which model system. The color-filled boxes describe the inputs (IN) 
and outputs (OUT) of signaling pathways that are mediated via c-Myc. Green: known 
functions (described above); orange: speculations on c-Myc functions from other models; 
blue: our main finding during lactation. Detailed description: see Introduction Chapter V. 
mammary gland suggested a role at involution; it was shown that overexpression of 
c-Myc prior to weaning resulted in accelerated involution and increased levels of pro-
apoptotic proteins (Sutherland et al., 2006). The results suggested that c-Myc acts as 
a downstream mediator of Stat3 in promoting apoptosis in the mammary gland. A 
model of all possible c-Myc functions in normal mammary gland development is 
shown in Figure S5. 
 
                 
 
 
 
 
 
  
 To which extent are these three main phenotypes discussed above (apoptosis, 
proliferation, adhesion properties, shown in green in Figure S5) recapitulated in the 
CKO used in our studies? Despite the reports that suggest a role for c-Myc in 
involution and apoptosis, we did not detect major changes during involution in c-
Myc-deficient mice. However, it is possible that subtle effects might have been 
overlooked. It is difficult to study the complicated process of involution since the 
process can occur in a very non-uniform way. This is the case for inbred mouse 
strains and even more problematic in mice from a mixed background. In addition, it 
may well be that the mutant mice developed alternative pathways to compensate for 
c-Myc loss during involution.  
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 Regarding the effects on proliferation and differentiation observed by Blakely et 
al., we did not detect changes in BrdU incorporation during the proliferative burst at 
early lactation. This is consistent with many other studies that found c-Myc to be 
dispensable for proliferation in vivo (Baena et al., 2005; Bettess et al., 2005; Dubois 
et al., 2008; Oskarsson et al., 2006; Wilson et al., 2004) and suggests that 
proliferation during lactation proceeds via different pathways. The stage where we 
did find slower or delayed proliferation in mutant mice was during early second 
pregnancy. As discussed in the Research Article, it is possible that the phenotype 
observed in second pregnancy results from the decreased translation rate during the 
preceding lactation in which c-Myc-deficient cells could not prepare properly for 
efficient proliferation. Another possibility is that c-Myc is required during this phase 
of proliferation downstream of progesterone signaling (as c-Myc levels are normally 
high during early pregnancy (Master et al., 2002)). We also examined the protein 
levels of Caveolin1 as it was shown to be a repressed c-Myc target and it was 
changed in the c-Myc overexpressing mammary glands (Blakely et al., 2005). 
Interestingly, while no consistent results were obtained during a first pregnancy (Fig. 
S6A), a higher percentage of mutant mice showed elevated protein levels of Cav1 
during the second pregnancy (Fig. S6B) suggesting that this contributes to the strong 
phenotype observed. In agreement with Blakely et al. this would suggest that c-Myc 
indeed regulates differentiation by at least modulating Prl-Stat5 signaling via Cav1 
expression.  
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Figure S6: Western analysis of Caveolin1, a direct repressed c-Myc target.                      
(A) Mammary gland lysates from wild type (W) and mutant (M) mice obtained during first 
lactation were examined for Caveolin1 levels. Compared to the loading control α-tubulin, 
some mutant samples show higher levels of Caveolin1, marked with asterisks. (B) 
Caveolin1 levels in mammary glands of mice from second pregnancy and lactation. 
Although the loading is not equal, the difference in Caveolin1 is more striking than in first 
pregnancy. Caveolin1 seems to be higher in mutant mice from P(II)16.5 and L(II)3.5. 
Antibody: Caveolin1 (BD Bioscience, #610059). 
 
 
     
 
 
 
 
 
 
 Finally, to investigate the third main phenotype observed in other models, which 
is c-Myc’s effect on adhesion molecules, we performed Western analysis for β1-
integrin, as this was shown to be affected in other c-Myc models (Howard, 2008; 
Wilson et al., 2004). There was again high variability between different animals, but 
some c-Myc mutant mice displayed higher protein levels of β1-integrin (Fig. S7). 
While this result needs to be confirmed in a larger number of animals, it is interesting 
to speculate that by changing the adhesive properties of epithelial cells, including the 
progenitor cells (Pi-MECs), c-Myc might influence migration of the cells and 
interaction with the surrounding niches, as shown for the hematopoietic stem cells 
(Wilson et al., 2004). As β1-integrin was previously shown to be important in 
mammary epithelial and progenitor cells (Li et al., 2005), deregulation of β1-integrin 
* * * * 
* * * * 
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Figure S7: Western analysis of β1-integrin, a repressed c-Myc target.  (A, B) 
Mammary gland lysates taken from wild type (W), mutant (M) and heterozygous (H) mice 
at different time points of lactation were analyzed for β1-integrin levels. Compared to the 
loading control α-tubulin, some mutant mice show elevated protein levels of β1-integrin. 
Antibody: see (Graus-Porta et al., 2001).  
 
levels could as well contribute to the phenotype seen in c-Myc-deficient glands, 
especially regarding the progenitor cells. In summary, some aspects of the phenotype 
observed in our model are partly found also in other c-Myc models, while others, 
such as apoptosis, seemed not to be affected by c-Myc loss.  
 
    
 
 
 
 
  
 It is worth mentioning two important general points that could be considered in 
further studies on c-Myc in the mammary gland. First, our model used WAPiCre, 
which is hormonally induced during pregnancy and its expression therefore not 
subject to ectopic induction. Some open questions that remain would eventually be 
better addressed using an inducible system like MMTV-rtTA/TetO-Cre, in which Cre 
expression and recombination are induced by doxycycline administration at any time 
point. This would allow a specifically regulated c-Myc loss, and would enable us to 
look separately at its effect on pregnancy, lactation and involution. A second 
* * * * * 
* * * * * 
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drawback is that the mice were in a mixed background, making it hard sometimes to 
compare even wild type littermates to each other. Using mice in a pure background 
like FVBN could reduce the variation seen between animals and enhance the 
phenotype even further. Nevertheless, novel and exciting functions for c-Myc were 
discovered with our model. 
 
 We consider that a very interesting aspect discovered in our study is c-Myc’s 
effect on translation, and the specificity within it. It is well known that c-Myc affects 
ribosome biogenesis and translation on multiple levels (see e.g. Oskarsson and 
Trumpp, 2005), but from the various KO studies performed in different organs, 
changes in translation were only detected in the intestines (Muncan et al., 2006). This 
demonstrates again that c-Myc affects different cell types/organs in different, specific 
ways: during lactation when the mammary gland is devoted to biosynthetic activity 
and secretion, efficient translation is probably the most essential process. By 
performing qPCR we observed that various c-Myc targets that are involved in 
ribosome biogenesis and translation (see Table 1 in research article) were expressed 
to lower levels in mutant compared to WT glands. This led us to the hypothesis that 
by lowering many of the components needed for translation, loss of c-Myc decreases 
the general translation efficiency in mutant glands, which is confirmed by our results 
from polysome fractionation. It would be interesting to further confirm the effect on 
ribosomal subunits and investigate ribosomal numbers, for example, via electron 
microscopy. This was not possible in a quantitative way on the pictures we obtained 
for our vesicle-studies. Higher resolution and eventual staining of ribosomes would 
be necessary to count them in WT and mutant cells.  
  
 One novel aspect was that c-Myc affects translation efficiency of specific targets, 
such as milk proteins or enzymes involved in milk synthesis, while translation of 
house-keeping genes stays relatively constant. The possible mechanisms behind this 
observation are worth being discussed in more detail. We think that three different 
mechanisms are plausible. First, as discussed in detail in the Research Article, 
changing the availability of ribosomes might affect translation of most abundant, 
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highly upregulated mRNAs whose products are involved in milk synthesis, while 
other mRNAs, such as house-keeping genes, which are not upregulated during 
lactation, remain translated in constant manner (Stoelzle et al., 2009).  
  
 Second, a new mechanism of how c-Myc regulates gene expression was recently 
found by Cole and Cowling (Cole and Cowling, 2009; Cowling and Cole, 2007). 
They show that c-Myc induces methylation of the 5’ guanosine cap of mRNA, 
generating m7G-mRNA, which is necessary for efficient translation. Interestingly, c-
Myc induced cap methylation on 9 out of 10 analyzed targets, and this effect was in 
each case higher than the transcriptional increase in total mRNA (Cole and Cowling, 
2009). Furthermore, they showed that the increased cap methylation led to a shift of 
those mRNAs to bigger polysomes, meaning that by methylating its target gene 
mRNAs, c-Myc enhances their translation potential. Levels of GAPDH mRNA and 
7mG-mRNA were unresponsive to c-Myc and consequently mRNA distribution of 
GAPDH in the polysome profile was unchanged (Cole and Cowling, 2009). This 
means that traditional c-Myc targets (including also Scd, Fads2 and Elovl1) might be 
subject to c-Myc mediated cap methylation, and thereby shift to bigger polysomes. 
We hypothesize that this mechanism contributes to the polysomal shift we detected 
for some c-Myc targets, since their total mRNA levels between WT and mutant mice 
were unchanged. It would be essential to investigate the levels of 7mG-mRNA of 
those targets in c-Myc mutant and WT animals, to confirm whether c-Myc affects 
cap methylation in the mammary gland. In addition, the authors observed in their 
initial study that genes which are not described c-Myc targets were also affected by 
methylation changes, and higher protein levels were found while mRNA levels were 
constant (Cowling and Cole, 2007). Although this has yet to be shown, one can 
imagine that c-Myc regulates methylation of numerous ‘new’ targets (maybe 
including milk proteins?) that are not transcriptional targets.  
  
 Finally, there is a third possibility to achieve selective translation, which is via 
polyadenylation, a process highly investigated for milk proteins (for review see 
Rhoads and Grudzien-Nogalska, 2007). The poly(A) tail at the 3’end of mRNA is 
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another modification that strongly enhances translation initiation and mRNA 
stabilization. Milk proteins (most investigations concentrated on β-casein) were 
found to undergo various changes in poly(A) length, being predominantly 
polyadenylated and translated during lactation and subsequently becoming 
deadenylated. More recently, it was shown in CID9 cells that these changes were 
induced by lactogenic hormones (Choi et al., 2004). In this study, β-casein mRNA 
shifted to larger polysomes in response to insulin plus prolactin, while GAPDH 
mRNA was not affected. Furthermore, while total mRNA of β-casein did not 
increase, the poly(A) tail was found to be elongated and there was no effect on 
GAPDH poly(A) tail, suggesting that polyadenylation in response to hormones is 
indeed an important physiological stimulus of milk protein translation. How could 
loss of c-Myc interfere with this? To answer this question, it would be most 
important to analyze the poly(A) tails in the c-Myc mutant mice, to see if c-Myc is 
essential for the polyadenylation process itself, as a mediator of the yet unidentified 
pathways from insulin and prolactin receptor (model discussed in Rhoads and 
Grudzien-Nogalska, 2007). Another possible option is that c-Myc activates specific 
proteins that use the poly(A) tail to enhance translation efficiency and loss of c-Myc 
would result in decreased expression of those proteins. This would probably as well 
affect specifically mRNAs with long poly(A) tails, while mRNAs with short (or 
constant) poly(A) tails would, in theory, not be affected. An interesting candidate for 
this is the cytoplasmic poly(A) binding protein PABPC1, which is a direct c-Myc 
target, and was found in our model to be decreased in mutant mice. One of many 
functions of PABPC1 is binding poly(A) tails to ensure mRNA stability and 
formation of the translation complex; furthermore, more than one PABPC1 can bind 
on long poly(A) tails (Mangus et al., 2003). Thus, loss of c-Myc could result in 
insufficient PABP-occupation of poly(A) tails due to decreased levels of PABPC1, 
and it is possible that mRNAs which get highly polyadenylated during pregnancy and 
lactation are more sensitive to this change than mRNAs whose poly(A) tails do not 
change.    
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 Another relevant point for discussion is the comparison of our results to other 
published studies that showed a similar phenotype in the mammary gland, and which 
models were used to generate it. In this respect we will concentrate on two reports, 
describing mice with full body KO of Akt1 (Boxer et al., 2006) and USF2 (Upstream 
stimulatory factor, Hadsell et al., 2003). The protein kinase Akt is interesting as it 
impacts on c-Myc protein levels via different mechanisms (Wierstra and Alves, 
2008). Furthermore, Akt has been implicated in lipid metabolism in the mammary 
gland: expression of activated Akt induced a precocious and increased lipid synthesis 
in pregnant mammary glands (Schwertfeger et al., 2003). In contrast, KO of Akt1 
resulted in a lactation defect with mutant mothers having reduced total milk volume, 
but comparable levels of milk proteins and milk lipid, leading to a reduced pup 
weight-gain (Boxer et al., 2006). Similar to what we observed in c-Myc-deficient 
glands, the Akt1 mutant glands contained the same number of alveoli as WT glands, 
but alveoli were less distended. The authors went on to show that there was no effect 
on proliferation, apoptosis and differentiation status in Akt1 KO animals. Instead 
they found that glucose uptake was less efficient in the mutant glands, due to a 
decreased expression of the glucose transporter Glut1. In addition, fewer vesicles 
were found to bud from the endoplasmic reticulum, less lipid droplets were detected 
in the cytoplasm, and several enzymes involved in lipid metabolism were mis-
expressed in the Akt1-deficient glands. While an endocrine effect resulting from the 
full body KO cannot be excluded, it is still very interesting to discuss the similarities 
to the c-Myc CKO. Besides the lactation defect with reduced volume of otherwise 
identically composed milk, we observed a very similar pattern in the electron 
microscopy regarding the vesicles. Enzymes of the lipid metabolism were also 
affected in c-Myc mutant glands, although we did not detect expression changes but 
rather changes in translation efficiency. One striking point is the expression of Glut1, 
which is normally upregulated from virgin to lactating glands, and was shown to be 
regulated by Akt1, but is also a direct target of c-Myc (Slc2a1 on http://www.myc-
cancer-gene.org/index.asp). This led us to test Glut1 expression on lactation day 10.5 
in WT and mutant glands via immunofluorescence (Fig. S8).  
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Figure S8: Immunofluorescence for Glut1 on mammary glands. Frozen sections (10 
µm) of mammary glands obtained on lactation day 10.5 were stained for the Glut1 
glucose transporter. Every image belongs to a different animal, all four animals were 
littermates. There is a clear tendency of lower Glut1 expression in the mutant glands. 
Method: Slides were fixed in ice cold acetone for 5min. After washing with PBS and 
permeabilization in 0.1% Triton/PBS (15 min) slides were blocked for 2h at RT with 10% 
goat serum/PBS. Sections were incubated with primary antibody Glut1 (Alpha 
Diagnostics, GT11A) overnight at 4°C. Secondary ant ibody: anti-rabbit FITC (Molecular 
Probes). Nuclear counterstain: Hoechst. Images were obtained on an Axio Imager Z1 
microscope using an AxioCamMR3 camera. All images were acquired using the identical 
exposure time. Scale bar, 100 µm. 
 
       
 
 
 
 
 
 
 
 
 Indeed, in the analyzed mice there was a tendency for lower Glut1 expression in 
c-Myc mutant glands; however, the effect was not as strong as seen in the Akt1-
deficient glands and the required staining of frozen sections hindered our ability to 
confirm the results in more animals. While c-Myc has not been addressed in the study 
of Boxer et al., it is nevertheless interesting to speculate that Akt1 regulates Glut1, 
glucose uptake and lipid synthesis in part via c-Myc. 
  
 Another phenotype sharing some similarities to what is observed in c-Myc-
deficient glands was found in USF2 KO mice (Hadsell et al., 2003). This is worth 
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mentioning as USF2 is another B-HLH-LZ transcription factor related to c-Myc and 
can bind the same E-box element sequences; however, whether USF cooperates with 
or represses c-Myc mediated transcription is cell type and context dependent (Corre 
and Galibert, 2005). In USF2 KO animals, milk volume was decreased and milk 
contained lower levels of lactose, which is responsible for water influx into the milk 
vesicles (Hadsell et al., 2003). Furthermore, the authors observed a decrease in 
luminal alveolar area in the mutant glands and lower protein levels of the translation 
initiation factors eIF4E and eIF4G, which are known c-Myc targets. However, as 
these were not changed on the mRNA level in USF2-deficient mice, a direct 
(transcriptional) involvement of USF2 or c-Myc in this phenotype was questionable. 
We checked the mRNA levels of eIF4E or eIF4G via semi-quantitative RT-PCR in 
our c-Myc mutant glands, but we did not detect any consistent changes (data not 
shown). Since the USF2 KO was also a full body KO, like the Akt1 KO described 
above, a systemic function rather than a cell autonomous mechanism might have a 
role in the phenotype, for example via affecting blood oxytocin levels (Hadsell et al., 
2003). Nevertheless, this study provided us with some good ideas and methods for 
studying milk and mammary glands in mice displaying a lactation defect.              
  
 
 One remaining aspect, which was not addressed in our study, is the connection 
between c-Myc and breast cancer. Breast cancer is still one of the leading causes of 
death in women in the developed countries and elevated protein levels of c-Myc are 
found in a large fraction (> 50%) of breast tumors (for more details, see Introduction 
Chapter V: Hynes and Stoelzle, 2009). Furthermore, c-Myc might play a prominent 
role in the basal breast cancer subtype, since a recent study found high transcriptional 
activity of Myc within this subtype (Alles et al., 2009) leading to the hypothesis that 
Myc maintains proliferation in those tumors independently of ER signaling 
(Musgrove et al., 2008). Even though targeting TFs is not trivial, there are several 
strategies for targeting oncogenic c-Myc (Ponzielli et al., 2005). As the effects of c-
Myc loss on mammary gland physiology are relatively tolerable, making it 
theoretically a suitable target for inhibition, it would be interesting to investigate the 
Discussion 
 
 - 116 - 
impact of c-Myc on tumor growth. This question has already been addressed in other 
studies, with diverse results. It was shown that c-Myc-deficient skin was resistant to 
Ras-mediated tumorigenesis (Oskarsson et al., 2006). Furthermore, in a Ras-induced 
lung carcinoma model, pharmacological inhibition of c-Myc triggered rapid 
regression on established tumors without irreversible side-effects (Soucek et al., 
2008). In the mammary gland, there exists only one study that describes an effect of 
c-Myc loss on tumors, namely Notch-induced tumorigenesis. Using MMTV-Notch; 
mycfl/fl;WAPCre mice it was shown that c-Myc was indispensable for the 
development of Notch-driven mammary tumor (Klinakis et al., 2006). 
 
 As discussed in Chapter V of the introduction, c-Myc is located downstream of 
multiple signaling pathways, such as Wnt, ErbB2 and Notch signaling (Fig. S9). In 
MMTV-Wnt1 and MMTV-Neu mice, which develop spontaneous mammary tumors, it 
will be interesting to investigate the role of c-Myc during tumor growth. As 
inhibition or loss of c-Myc shows variable effects in different tumor models, one 
could imagine that loss of c-Myc prior to tumor formation could increase the latency; 
alternatively loss of c-Myc in established tumor could lead to growth arrest and 
eventually to tumor regression. However, this remains to be examined in detail in the 
mammary gland. Interestingly it has recently been shown that c-Myc is an important 
effector of tumorigenesis driven by Apc loss in the intestines (Sansom et al., 2007), 
while it is totally dispensable after Apc loss in the liver where most Wnt targets were 
β-catenin dependent and c-Myc independent (Reed et al., 2008).     
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adapted from Hynes and Stoelzle, 2009 
 
Figure S9: Simplified model showing the central role of c-Myc in different signaling 
pathways known to be important in breast cancer. The role of c-Myc in Notch-induced 
mammary tumorigenesis has been described (see text for details). c-Myc is also a well 
described downstream mediator of ER signaling in breast cancer cells. The importance of 
c-Myc in tumor models induced by Wnt or ErbB2 remains to be shown. Detailed 
description and additional information: see Introduction Chapter V.  
 
 
 
                
 
 
  
 
  
  
 To conclude, our study suggests that c-Myc plays different important roles during 
mammary gland development which fall into 3 major functional areas: cell cycle, 
translation/metabolism and progenitor cells. Apart from a lactation defect, the effects 
of c-Myc loss are relatively mild and well tolerated as no apoptosis or dramatic tissue 
loss was observed. This is of special interest when considering c-Myc as a target in 
breast cancer therapy. Especially in the aggressive basal subtype of breast cancer, 
which cannot be treated with a targeted therapy like tamoxifen or trastuzumab, high 
pathway activation of c-Myc was found (Alles et al., 2009). Also, deregulation of c-
Myc pathway was specifically detected in younger (<45 years) patients (Anders et 
al., 2008). In addition, apart from being a direct target of inhibition, c-Myc has been 
considered as a biomarker of basal breast tumors that might be able to predict 
response to certain chemotherapies (recently discussed in Bouchalova et al., 2009). 
Further studies and clinical trials will be necessary to clarify the importance of c-Myc 
as a therapeutic or predictive target in breast cancer.   
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